Page last updated: 2024-12-05

floxuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5790
CHEMBL ID917
CHEBI ID60761
SCHEMBL ID4424
MeSH IDM0008626
PubMed CID643968
SCHEMBL ID2056715
MeSH IDM0008626

Synonyms (160)

Synonym
MLS002695934
AC-16391
SRI-9246-15
MLS000069439 ,
nsc 27640
floxuridin
nsc27640
fluorodeoxyuridine
5-fluorouracil 2'-deoxyriboside
fdurd
fudr
2'-deoxy-5-fluorouridine
fdur
nsc-27640
deoxyfluorouridine
fluoruridine deoxyribose
5-fluoro-2-deoxyuridine
5-fluoro-durd
5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
5fdu
floxuridine (usp/inn)
fudr (tn)
D04197
5-fdurd
1beta-d-2'-deoxyribofuranosyl-5-flurouracil
beta-5-fluoro-2'-deoxyuridine
1-beta-d-2'-deoxyribofuranosyl-5-flurouracil
5-fluoro-2'-deoxy-beta-uridine
1-(2-deoxy-beta-d-ribofuranosyl)-5-fluorouracil
floxuridine
50-91-9
5-fluorodeoxyuridine
5 fluorodeoxyuridine
5-fluoro-2'-deoxyuridine, thymidylate synthase inhibitor
fdu ,
NCGC00023722-06
5-fluoro-2-desoxyuridine
NCGC00023722-05
DB00322
einecs 200-072-5
floxiridina [inn-spanish]
ai3-50691
hsdb 3227
5-fluor-1-(beta-2'-deoxyribofuranosyl)pyrimidin-2,4(1h,3h)-dion [czech]
brn 0090221
floxuridinum [inn-latin]
smr000059051
NCGC00023722-03
HMS2090I12
CHEMBL917 ,
CHEBI:60761 ,
floxiridina
floxuridinum
D2235
STK801909
AKOS005622662
1-[(4s,2r,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-1,3-dihydropyri midine-2,4-dione
5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
EN300-52649
bdbm50340678
5-fluoro-2''-deoxy-uridine
5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidine-2,4-dione
2''-deoxy-5-fluorouridine
5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
5-fluoro-2''-deoxyuridine
1-(beta-d-2-deoxy-erythro-pentofuranosyl)-5-fluorouracil
5-fluoro-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidine-2,4-dione
cas-50-91-9
dtxcid603057
dtxsid3023057 ,
tox21_110892
HMS2230N22
BCP9000691
(+)-5-fluorodeoxyuridine
2'-deoxy-5-fluoro-d-uridine
2-deoxy-5'-fluorouridine
(+)-5-fluoro-2'-deoxyuridine
BCP0726000269
floxuridine (fludara)
floxuridine [usan:usp:inn]
039lu44i5m ,
5-24-06-00291 (beilstein handbook reference)
uridine, 2'-deoxy-5-fluoro
unii-039lu44i5m
5-fluor-1-(beta-2'-deoxyribofuranosyl)pyrimidin-2,4(1h,3h)-dion
EPITOPE ID:138108
S1299
gtpl4801
floxidine
2'-deoxy-5-fluoro uridine
ODKNJVUHOIMIIZ-RRKCRQDMSA-N
floxuridine [who-dd]
floxuridine [vandf]
floxuridine [usan]
floxuridine [usp monograph]
floxuridine [hsdb]
floxuridine [usp-rs]
floxuridine [usp impurity]
floxuridine [mi]
floxuridine [inn]
floxuridine [mart.]
floxuridine [orange book]
CCG-220965
BBL033765
HY-B0097
CS-1827
SCHEMBL4424
NCGC00023722-08
tox21_110892_1
J-700034
MLS006011768
PS-7520
SRI-9246_18
OPERA_ID_1559
mfcd00006530
136353-77-0
SR-01000000001-2
sr-01000000001
floxuridine, united states pharmacopeia (usp) reference standard
HMS3715A11
BRD-K47832606-001-26-9
Q5462356
floxuridine,(s)
BCP02871
BRD-K47832606-001-30-1
floxuridina
fluorouridine deoxyribose
floxuridinum (inn-latin)
5-fluorouridine deoxyribose
2-deoxy-5-fluorouridine
floxuridine (mart.)
wr-138720
1-beta-d-2'-deoxyribofuranosyl-5-fluorouracil
l01bc09
floxuridine (usp impurity)
floxuridine (usp monograph)
floxuridine (usp-rs)
floxuridine (usan:usp:inn)
floxiridina (inn-spanish)
Z756475348
BP-58649
uridine, 2'-deoxy-5-fluoro-
ro 5-0360
5-fluorouracil deoxyriboside
5-fudr
5-fluoro-2'-deoxyuridine ,
uridine, 2'-deoxy-5'-fluoro-
2'-deoxy-5-fluoro-(6cl,7cl,8cl,9cl) uridine
5-flurouracil-2'-deoxyriboside
MLS001304108
smr000542970
AKOS004119882
SCHEMBL2056715
1-(2-deoxy-d-erythro-pentofuranosyl)-5-fluoro-4-hydroxypyrimidin-2(1h)-one
STL529010
AKOS037495464
688007-28-5
EN300-37158599
5-fluoro-1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione

Research Excerpts

Overview

Floxuridine is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction. It is a fluoropyrimidine active on human colorectal cancer, a tumour which metastasises first to the liver.

ExcerptReferenceRelevance
"Floxuridine is a very effective drug with high potency in the treatment of various tumors but its utility is limited by its low efficiency of cellular uptake. "( Lipophilic Prodrug of Floxuridine Loaded into Solid Lipid Nanoparticles:
Barge, A; Battaglia, L; Chirio, D; Dianzani, C; Ferrara, B; Gallarate, M; Giordano, S; Peira, E; Sapino, S, 2018
)
2.24
"Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction."( The role of floxuridine in metastatic liver disease.
Kemeny, NE; Power, DG, 2009
)
1.45
"Floxuridine is a fluoropyrimidine active on human colorectal cancer, a tumour which metastasises first to the liver."( Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases.
Busi, C; Di Stefano, G; Fiume, L, 2002
)
2.48
"Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases. "( Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs.
Amidon, GL; Landowski, CP; Song, X; Vig, BS, 2005
)
2
"Floxuridine (FUDR) is an analogue of 5-FU, used for arterial hepatic infusion in patients affected by liver metastases from colorectal cancer."( Localized hand-foot syndrome after intra-arterial hepatic chemotherapy with floxuridine: a clinical case.
Bareggi, C; Garassino, MC; Ghidini, A; Mora, M; Paleari, D; Pancera, G; Salamina, S; Senecione, M,
)
1.08
"Floxuridine (5-FUDR) is an antipyrimidine used in the treatment of metastatic colorectal carcinoma. "( Radiologic manifestations of small-bowel toxicity due to floxuridine therapy.
Gluck, WL; Gramm, HF; Kelvin, FM; Lokich, JJ, 1986
)
1.96

Actions

ExcerptReferenceRelevance
"A floxuridine assay with a lower boundary of detection of 0.250 ng/mL was developed."( Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases.
Bruijn, P; Buisman, FE; Doorn, LV; Doornebosch, PG; Filipe, WF; Grootscholten, C; Grünhagen, DJ; Holster, JJ; Homs, MYV; IJzerman, NS; Koerkamp, BG; Kok, NFM; Koolen, SLW; Kuhlmann, KFD; Mathijssen, RHJ; van Bommel, CPE; Verhoef, C, 2023
)
1.79

Toxicity

The aim of this study was to quantitatively assess spontaneous functional hepatic arteriovenous shunting in patients with liver metastases. The goals were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival.

ExcerptReferenceRelevance
" The administration of 5'-DFUR resulted in damage to the intestinal mucosal membrane and diarrhea in normal mice, whereas Ro 09-1390 was much less toxic to the intestinal tract."( Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Eda, H; Fujimoto, K; Ishida, M; Ishitsuka, H; Miwa, M; Ninomiya, Y; Sahara, H; Umeda, I; Yokose, K, 1990
)
0.28
" However, a WHO grade 4 hematologic toxicity was observed in 9 patients, and 2 toxic deaths were related to severe granulocytopenia and sepsis."( [Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect].
Alberto, P; Mermillod, B; Winkelmann, JJ, 1990
)
0.28
" FdUrd, in particular, had a very minor effect on rRNA production even at very toxic drug concentrations."( Correlation between ribosomal RNA production and RNA-directed fluoropyrimidine cytotoxicity.
Armstrong, RD; Cadman, EC; Takimoto, CH; Tan, YY, 1987
)
0.27
" Toxic effects were hepatocyte necrosis, steatosis, cholestasis, central vein sclerosis, and alterations in the portal triad."( Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR.
Doria, MI; Levin, B; Riddell, RH; Shepard, KV, 1986
)
0.27
" 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines."( [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988
)
0.27
" Virtually non toxic concentrations of dThd potentiated the cytotoxicity of MNNG more than 10-fold but that of MMS was potentiated only about 2-fold showing that O-alkylation of DNA was associated not only with the facilitation of mutagenesis but also with the potentiation of cytotoxicity."( Deoxyribonucleoside-induced selective modulation of cytotoxicity and mutagenesis.
Danenberg, PV; Ibric, LL; Peterson, AR; Peterson, H, 1985
)
0.27
" All three tumor cell lines were more sensitive to OHUrd than were the FeInt cells, whereas 5-FU was more toxic to the latter."( Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells.
Giovanella, BC; Lockshin, A; Mendoza, JT; Stehlin, JS; Warneke, C,
)
0.13
" With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor."( 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Armstrong, RD; Cadman, E, 1983
)
0.27
" FUdR was found to be chemically toxic in itself to 2 canine tissue culture lines at doses used in the literature to increase 125IUdR uptake."( The toxicity of fluorodeoxyuridine when used to increase the uptake of 125I-iododeoxyuridine into tissue culture cells in vitro.
Holmes, JM, 1983
)
0.27
" The results indicate that immunotoxic profiles of Ro 09-1390 and 5'-DFUR are very similar and characterized primarily by myelotoxicity and Ro 09-1390 is approximately two-times less toxic than 5'-DFUR on a molar basis in BDF1 mice."( Comparative immunotoxicity assessment of N4-Trimethoxybenzoyl-5'-deoxy-5- fluorocytidine (Ro 09-1390) and 5'-deoxy-5-fluorouridine (5'-DFUR) in BDF1 mice.
Anderson, TD; Hayes, TJ; Horii, I; Inoue, T, 1996
)
0.29
"The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival."( Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity.
Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996
)
0.9
" 5-fluoro-2'-deoxyuridine is an active drug in the treatment of solid tumours, but with toxic effects on intestine and bone marrow."( Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas.
Busi, C; Derenzini, M; Di Stefano, G; Fiume, L; Trerè, D, 1998
)
0.3
" The aim of this study was to quantitatively assess spontaneous functional hepatic arteriovenous shunting in patients with liver metastases and to determine its implication in the increase in systemic toxic effects of intra-arterial infusion chemotherapy with floxuridine."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.48
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Therapeutic safety was evaluated by analyses of adverse events with the recommended dose."( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006
)
0.33
" No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients."( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006
)
0.33
" Capecitabine was less toxic in monkeys than oral 5'-DFUR according to dose (mmol/kg) and 5'-DFUR AUC."( Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Horii, I; Kawashima, A; Kobayashi, K; Nakano, K; Shindoh, H; Shishido, N, 2006
)
0.33
" We present a colon cancer patient with the UGT1A1 polymorphism (UGT1A1 *28) as a known high risk for irinotecan, who was treated with a combination of doxifluridine and irinotecan for peritoneal dissemination resulting in stable disease for 2 years without adverse reactions, although the patient initially developed severe adverse effects to the combination of the protracted venous infusion of 5-FU and irinotecan."( Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H, 2006
)
0.33
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Thymidine promotes microbial conversion of the prodrug FUdR into toxic 5-fluorouridine-5'-monophosphate (FUMP), leading to enhanced host death associated with mitochondrial RNA and DNA depletion, and lethal activation of autophagy."( Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion.
Benjamin, SB; Drangowska-Way, A; Hilzendeger, MA; Joshi, C; Ke, W; Lewis, N; Locasale, J; Mony, VK; O'Rourke, EJ; Patti, GJ; Saba, JA; Yao, CH; Zhang, S, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."( Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989
)
0.28
" The elimination half-life time for 5-FU was protracted by a factor of 2-3 compared with the direct injection of 5-FU."( Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month.
Aas, M; Flokkmann, A; Fosså, SD; Heier, M; Heintz, R; Linder-Ciccolunghi, S; Moe, B, 1986
)
0.27
" Furthermore the differing levels of 5-FU metabolites in normal and malignant tissue could not be correlated with the pharmacokinetic parameters studied."( The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.
Chisholm, EM; Finan, PJ; Giles, GR; Woodhouse, L, 1987
)
0.27
" The tolerance and pharmacokinetic profile of IP 5-fluoro-2'-deoxyuridine(FUDR) alone and with (R,S)-leucovorin ((R,S)-LV) have each been evaluated in previous phase I studies."( Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.
Chan, KK; Israel, VK; Jeffers, S; Jiang, C; Leichman, CG; Leichman, L; Morrow, CP; Muggia, FM; Roman, L; Tulpule, A, 1995
)
0.29
" Pharmacokinetic parameters showed very wide interpatient variability."( Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.
Creaven, PJ; Frank, C; Levine, EG; Meropol, NJ; Petrelli, NJ; Proefrock, A; Raghavan, D; Rodriguez-Bigas, M; Rustum, YM; Udvary-Nagy, S, 1994
)
0.55
" The absorption and pharmacokinetic parameters of 5'-DFUR and its active metabolite 5-FU, after administration of 5'-DFUR in combination with AcyT, were evaluated in the animals."( Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Fukushima, S; Hamada, A; Kawaguchi, T; Morinaga, A; Nakano, M; Saneyoshi, M, 1993
)
0.29
"Using positron emission tomography and radio-high performance liquid chromatography, the accumulation of 2'-deoxy-5-18F-fluorouridine in the brain tumors and plasma pharmacokinetic parameters were investigated in 20 patients."( Brain tumor accumulation and plasma pharmacokinetic parameters of 2'-deoxy-5-18F-fluorouridine.
Ido, T; Ishiwata, K; Iwata, R; Kameyama, M; Sato, K; Takahashi, T; Tsurumi, Y; Yoshimoto, T, 1993
)
0.29
" Here I briefly review molecular, cellular, and organismic time-keeping mechanisms as well as cytokinetic, pharmacokinetic, and pharmacodynamic data, which support the predictable and exploitable nonlinear dynamic relation between dose and effect that occurs each day."( Circadian pharmacodynamics of anticancer therapies.
Hrushesky, WJ, 1993
)
0.29
" It was expected that AcyT would only inhibit the phosphorolytic degradation of 5'-DFUR to 5-FU, but the effect was more evident on the pharmacokinetic parameters of 5-FU than on those of 5'-DFUR."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.29
" Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508."( Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996
)
0.29
"A pharmacokinetic analysis program based on a tank-in-series model, MULTI(TIS), was developed for the evaluation of dose-dependency in the local disposition of a drug."( Pharmacokinetic analysis program based on tank-in-series model, MULTI(TIS), for evaluation of capacity-limited local disposition.
Fukumura, K; Higashimori, M; Nakagawa, T; Yamaoka, K, 1998
)
0.3
" None of the demographic or biologic parameters considered was significantly related to pharmacokinetic parameters."( Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Bajetta, E; Colleoni, M; de Braud, F; Guenzi, A; Stampino, CG; Zampino, MG,
)
0.13
"A large interpatient pharmacokinetic variability was observed without any significant correlation with the clinical parameters studied."( Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Bajetta, E; Colleoni, M; de Braud, F; Guenzi, A; Stampino, CG; Zampino, MG,
)
0.13
" The mean elimination half-life of intravenous dFUrd increased with the dose from 15 to 22 min."( Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
De Bruijn, EA; Highley, MS; Maes, RA; Reeuwijk, HJ; Tjaden, UR; Van Der Heyden, SA; Van Oosterom, AT; Van Slooten, H, 1999
)
0.3
"Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study."( Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Au, JL; Weaver, JR; Wientjes, MG, 1999
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.31
" Systemic exposure based on plasma concentrations of capecitabine and its metabolites was determined using individual parameter estimates derived from a population pharmacokinetic model constructed for this purpose in NONMEM."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" Plasma concentration data were pooled and analyzed using a population pharmacokinetic program (NONMEM)."( Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Delaloge, S; Di Palma, M; Forgue, ST; Le Chevalier, T; Llombart, A; Ni, L; Tourani, JM; Turpin, F, 2004
)
0.32
" Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels."( S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004
)
0.32
" To determine the plasma dihydrouracil/uracil ratio (DUUR) as a potential index for setting 5-FU/FUDR doses, the authors conducted a prospective study on the relationships of the DUUR with 5-FU/FUDR pharmacokinetic and pharmacodynamic parameters."( Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Hu, P; Jiang, H; Jiang, J; Lu, J, 2004
)
0.32
" Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3."( Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N, 2005
)
0.33
"Forty patients and 75 pharmacokinetic time-courses were available for analysis."( Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Lokiec, F; Rezaí, K; Urien, S, 2005
)
0.33
" Due to these pharmacokinetic merits, capecitabine can be given at a higher dose, and therefore is expected to yield higher antitumor activity, than doxifluridine."( [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Ebi, H; Minami, H, 2005
)
0.33
" Furthermore, the intracellular accumulation of the active metabolite gemcitabine triphosphate, as a surrogate pharmacodynamic endpoint, was also determined in vitro in canine melanoma cells."( Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
Freise, KJ; Martín-Jiménez, T, 2006
)
0.33
"The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies."( The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007
)
0.34
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" All patients were assessable for toxicity and pharmacokinetic analysis."( Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M, 2009
)
0.35
" The investigation of the carrier biodistribution and the drug pharmacokinetic profile furnished the rationalization of the efficacy of the vesicular system containing the active compound 10-fold less concentrated; in fact, liposomes promoted the concentration of the drug inside the tumor and they increased its plasmatic half-life."( Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Celia, C; Cosco, D; Costante, G; Filetti, S; Fresta, M; Iannone, M; Paolino, D; Puxeddu, E; Racanicchi, L; Russo, D; Trapasso, E, 2010
)
0.36
" Genetic polymorphisms of DCK and SLC29A1 (hENT1) had no significant correlation with gemcitabine pharmacokinetic parameters."( Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T, 2010
)
0.36
"A population pharmacokinetic model that included CDA genotypes as a covariate for gemcitabine and dFdU in Japanese cancer patients was successfully constructed."( Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T, 2010
)
0.36
"To develop and internally validate a population pharmacokinetic model for gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU); and to evaluate its predictive perfomance for personalizing the dosage used in cancer patients."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
" A 2-compartment pharmacokinetic model was implemented in the NONMEN VI program to determine the appropriate pharmacokinetic parameters."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
" Internal validation confirmed that the population pharmacokinetic model was appropriate for describing the plasma concentrations of gemcitabine and dFdU over time, as well as its variability in the study population."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
"The population pharmacokinetic model adequately characterised the gemcitabine and dFdU plasma concentrations in the study population over time, and can be used to accurately and precisely optimise gemcitabine dosing regimens in cancer patients."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
"The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy."( Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Dudek, AZ; Greeno, EW; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Mitra, AK; Skubitz, KM, 2012
)
0.38
" The purpose of this study was to investigate the pharmacokinetic properties of doxifluridine and its two major metabolites, 5-FU, and 5-fluorouridine (5-FUrd), in beagle dogs following a single oral administration of 200 mg doxifluridine capsule (Furtulon(®))."( Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.
Baek, IH; Kim, MS; Kwon, KI; Lee, BY, 2013
)
0.39
"Nine patients treated with CCB and BVZ for advanced colorectal cancer entered this pharmacokinetic study."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" After repeated cycles of BVZ no significant pharmacokinetic interaction was observed."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
"From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (dFCR), 5'-deoxy-5-fluorouridine (dFUR), 5-FU, and fluoro-β-alanine (FBAL) using data from a heterogeneous population of cancer patients (n = 237) who participated in seven clinical studies."( Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM, 2019
)
0.51
" We successfully applied the validated method to the analysis of dFdC and dFdU in mouse plasma, brain, and brain tumor tissue in a preclinical pharmacokinetic study."( LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study.
Davis, A; Gibson, EG; Roussel, MF; Stewart, CF; Zhong, B, 2021
)
0.62
" Pharmacokinetic parameters were estimated using non-compartmental analysis."( Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Beijnen, JH; Derissen, EJ; Huitema, AD; Jacobs, BA; Rosing, H; Schellens, JH, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out."( [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992
)
0.28
" When 50 U/ml IFN-gamma were combined with 5-FU or FUdR, the antiproliferative effects were synergistic in those cell lines with sensitivity to IFN-gamma as a single agent, but not in the IFN-gamma-insensitive cell lines."( The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines.
Boven, E; Haisma, HJ; Maas, IW; Pinedo, HM; Schlüper, HM, 1991
)
0.28
"We investigated the antitumor activities of 5-fluorouracil (5-FU), 5'-deoxy-5-fluorouridine (5'-DFUR), 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) in combination with hyperthermia in vitro."( Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro.
Akazai, Y; Fuchimoto, S; Iwagaki, H; Matsubara, N; Orita, K; Shiiki, S; Watanabe, T, 1991
)
0.28
"The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse."( Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989
)
0.28
" Four cycles of the regimen I drug combination failed to prolong life due to toxic side effects in every cancer line."( [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987
)
0.27
"Antitumor effects of oral fluorinated pyrimidines including 5'-DFUR and their combination with recombinant interferon (rIFN) alpha A/D (Bgl) or cytostatics were investigated using various tumor models in mice."( [Antitumor effects of 5'-deoxy-5-fluorouridine (5'-DFUR) against various murine tumors in combination with recombinant interferon alpha or cytostatics].
Eda, H; Fukuda, H; Ishikawa, T; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Tanaka, Y, 1987
)
0.27
" The increase in lifespan (ILS) of mice treated with 5'-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5'-DFUR alone was only 48% in the P388 leukemia system."( Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Iigo, M; Ishitsuka, H; Miwa, M; Nitta, K, 1987
)
0.27
"3 microM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 microM hypoxanthine fully protected sensitive cells from greater than 99% methotrexate-induced cell lethality."( Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine.
Bertino, JR; Handschumacher, RE; Sobrero, AF, 1985
)
0.27
"Modulation of the therapeutic efficacy of cisplatin (CDDP) and 5-fluoro-2'-deoxyuridine (FdUrd) alone and in combination with N-phosphonacetyl-L-aspartate (PALA) was evaluated in mice bearing colon carcinoma (C-26) using a weekly intravenous (i."( Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA, 1995
)
0.29
" Combination with high-dose 5'-DFUR and low-dose intra-hepatic arterial infusion of CDDP is considered a very effective chemotherapy which can be performed ambulatorily while maintaining the quality of life of patients with liver metastases of gastric cancer."( [Combination with intra-hepatic arterial infusion of low-dose cisplatin and oral administration of high-dose doxyfluridine in patients with liver metastases of gastric cancer].
Kikkawa, N; Kobayashi, K; Mishima, H; Shin, E; Takatsuka, Y; Tamaki, Y; Tono, T; Yagyu, T, 1994
)
0.29
" These results provide a rationale for using short duration of FUdR in combination with other drugs."( Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance.
Arisawa, Y; Dalton, RR; Sigurdson, ER; Sutanto-Ward, E, 1994
)
0.29
"In vivo antitumor activity of pirarubicin (THP) and epirubucin (EPI) in combination with doxifluridine (5'-DFUR) and cisplatin (CDDP) were examined using mouse P388 leukemia."( Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata, N; Hirano, S; Iguchi, H; Izumi, H; Mase, T; Takeuchi, T; Tone, H, 1995
)
0.29
"The antitumor activity of recombinant human interleukin 2 (rIL-2) in combination with 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR) against marine colon carcinoma 26 (Colon 26) was studied."( Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.
Fujiwara, K; Gotoh, K; Houkan, T; Midoro, K; Ootsu, K; Yukishige, K, 1997
)
0.3
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."( [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002
)
0.31
"Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)."( Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002
)
0.51
" The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest."( Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.
Danenberg, KD; Danenberg, PV; Grem, JL; Kao, V; Nguyen, D, 2002
)
0.31
"We designed a new regimen to evaluate the efficacy and feasibility of weekly paclitaxel combined with orally administered 5'-DFUR therapy against advanced and recurrent gastric cancer."( [Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Tsubono, M; Yasumizu, R, 2005
)
0.33
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" The good response rate and long time to progression and overall survival time of this doxifluridine combined with weekly paclitaxel therapy indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients."( Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008
)
0.35
"The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.36
" The antitumor and anti-angiogenic effects of metronomic doxifluridine (delivered via oral gavage) in combination with TNP-470 were evaluated in vivo."( Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Choijamts, B; Emoto, M; Kawarabayashi, T; Miyamoto, S; Naganuma, Y; Nakajima, K; Ogata, S; Shirota, K, 2011
)
0.37
" The efficacy of weekly paclitaxel in combination with doxifluridine (5'-DFUR) in gastric cancer patients with malignant ascites was evaluated."( Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D, 2011
)
0.37
"Weekly paclitaxel in combination with doxifluridine is effective for gastric cancer patients with malignant ascites with an acceptable toxicity profile."( Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D, 2011
)
0.37
" Taken together, these studies 1) identify DNA repair and checkpoint pathways that are important in ovarian cancer cells treated with FdUrd, ABT-888, and F+A, 2) show that disabling HR at the level of ATR, BRCA1, BRCA2, or RAD51, but not Chk1, ATM, PTEN, or FANCD2, sensitizes cells to ABT-888, and 3) demonstrate that even though ABT-888 sensitizes ovarian tumor cells with functional HR to FdUrd, the effects of this drug combination are more profound in tumors with HR defects, even compared with other chemotherapy + ABT-888 combinations, including cisplatin + ABT-888."( Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls, AM; Huntoon, CJ; Karnitz, LM; Wagner, JM, 2012
)
0.38
" In the present study, to address this concern, we proposed a novel strategy of preparing self-assembled nanoparticles from amphiphilic drug-drug conjugate for synergistic combination chemotherapy."( Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.
Hu, M; Huang, P; Su, Y; Wang, Y; Yan, D; Zhou, L; Zhu, X, 2015
)
0.66
" This study aimed to compare the overall survival (OS) of HAI-FUDR in combination with modern systemic CT versus modern systemic CT alone in patients with IU-CRCLM."( Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH, 2017
)
0.46
"In this case-control study of patients with IU-CRCLM, HAI in combination with CT was associated with improved OS when compared with modern systemic CT alone."( Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH, 2017
)
0.46
"To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC."( Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020
)
0.82

Bioavailability

A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the improvement of oral bioavailability and the feasibility of target drug delivery via oligopeptide transporters. The results show that, in the metastatic liver, arterial bioavailability of D-sorbitol varies widely.

ExcerptReferenceRelevance
" After a 700-mg/kg rectal dose, the terminal half-life was 430 min, the bioavailability was 30%, and the fraction of the dose recovered in 24-hr feces was 34%."( Absorption of 5'-deoxy-5-fluorouridine from colon.
Au, JL; Gunnarsson, LC, 1989
)
0.28
" UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55."( Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.
Au, JL; Bramer, SL; Wientjes, MG, 1988
)
0.27
" Because of the high bioavailability and low toxicity of oral doxifluridine we conducted this phase II trial to evaluate the feasibility, toxicity and activity of a home therapy with oral doxifluridine in elderly metastatic colorectal cancer patients."( Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994
)
0.29
" The bioavailability of oral idarubicin and of oral doxifluridine allows for their use in an oral 3 drug regimen."( Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Alberto, P, 1993
)
0.29
" The circadian rhythm of these key enzymes of pyrimidine metabolism, the interrelationship of their activities, and their role in the regulation of uridine bioavailability could be of particular significance in modulating the therapeutic regimens with 5-fluorinated pyrimidines."( Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines.
el Kouni, MH; Naguib, FN; Soong, SJ, 1993
)
0.29
" AcyT increased the maximal plasma concentration (Cmax) and apparent absorption rate constant (ka) of 5'-DFUR, as expected, but the increase in AUC (area under the curve) was not significant."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.29
" The extent of systemic bioavailability (F) of 5'-DFUR was estimated to be 75."( Moment analysis of intestinal first-pass metabolism by portal-systemic concentration difference in single conscious rat using 5'-deoxy-5-fluorouridine and 5-fluorouracil as model drug system.
Nakagawa, T; Sawai, Y; Takemura, A; Yamaoka, K, 1997
)
0.3
" The mean systemic bioavailability of oral dFUrd was 34-47%."( Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
De Bruijn, EA; Highley, MS; Maes, RA; Reeuwijk, HJ; Tjaden, UR; Van Der Heyden, SA; Van Oosterom, AT; Van Slooten, H, 1999
)
0.3
" Functional hepatic arterio-venous shunting was evaluated through the bioavailability of intra-arterially administered D-sorbitol, a safe, natural compound whose kinetic features make its hepatic clearance flow dependent."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.3
"Our results show that, in the metastatic liver, arterial bioavailability of D-sorbitol, an index of functional arteriovenous shunting, varies widely, is significantly greater in patients with massive liver occupation and it is a good predictor of systemic toxicity of intra-arterial regional chemotherapy with floxuridine."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.48
" The absorption rate of dFUR, analyzed by the Loo-Riegelman method, suggests that drug absorption took place in part by saturable mechanisms."( Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats.
Au, JL, 1987
)
0.27
" One limitation to its use is the necessity of co-injecting cimetidine to increase its bioavailability and hence its sensitivity for PET detection."( Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model.
Bergström, M; Borbath, I; Grégoire, V; Långström, B; Laryea, D; Pauwels, S, 2002
)
0.31
"Amino acid ester prodrugs of antiviral and anticancer nucleoside drugs were developed to improve oral bioavailability or to reduce systemic toxicity."( Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
Amidon, GL; Drach, JC; Kim, JS; Shin, HC; Song, X; Vig, BS, 2006
)
0.56
"A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the improvement of oral bioavailability and the feasibility of target drug delivery via oligopeptide transporters."( Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters.
Amidon, GL; Hilfinger, JM; Landowski, CP; Ramachandran, C; Sun, J; Tsume, Y; Vig, BS, 2008
)
0.83
" The high bioavailability (~90%) following oral dosing with RFUdR indicates that this DAMM prodrug may be suitable for oral dosing to deliver FUdR and RA for cancer chemotherapy."( Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice.
Knaus, EE; Wiebe, LI; Xia, Z, 2013
)
0.39
" Average bioavailability was assessed by ANOVA."( Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Baken, BC; Erlinghagen, V; Fuhr, U; Kubeš, V; Novotný, V; Peroutka, R; Queckenberg, C; Van Os, SH; Wargenau, M, 2015
)
0.42
" Through structure optimization, the o-methylbenzyl analog (1t) was identified as an orally bioavailable and liver-targeted lead compound."( Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J, 2016
)
0.43
"To improve bioavailability and provide resistance to deamination, an array of gemcitabine (dFdC) prodrugs carrying the acyl modifications has been successful in the optimization of pharmacokinetic properties of dFdC, but the reports about 4-N-carbobenzoxy-dFdC (Cbz-dFdC), a dFdC prodrug bearing alkyloxycarbonyl modification, are relatively rare."( Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Aa, L; Fei, F; Hao, K; Jiang, W; Liu, J; Lu, L; Pei, X; Peng, Y; Sun, Y; Wang, G; Wang, J; Zhen, L, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Through structure optimization, the o-methylbenzyl analog (1t) was identified as an orally bioavailable and liver-targeted lead compound."( Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J, 2016
)
0.43

Dosage Studied

The authors suggest investigation of an alternate drug schedule. Medical oncology experience in floxuridine dosing is critical in maximizing the treatment doses and the number of cycles administered while avoiding biliary toxicity.

ExcerptRelevanceReference
"Evidence is presented that the increase in specific activity of N-acetylglutamate synthase observed upon heat induction of Escherichia coli (lambdadargA) is primarily due to a gene dosage effect."( Expression of the argA gene carried by a defective lambda bacteriophage of Escherichia coli.
Haas, D; Kelker, N; Leisinger, T, 1976
)
0.26
" Dose-response curves for each agent indicate the following absolute potency: FUDR greater than FUR greater than ARA-C greater than 5-FU = bleomycin greater than DFUR."( Evaluation of antiproliferative agents using a cell-culture model.
Senderoff, RI; Smith, DR; Sokoloski, TD; Weber, PA, 1990
)
0.28
" Treatment with doxifluridine at a dosage of 3000 mg/m2 given intravenously for 5 successive days at 3-week intervals led to 6 partial remissions (17%)."( Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer.
Neijt, JP; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vermorken, JB; Willemse, PH, 1991
)
0.28
" This was deemed due to the small dosage and a short duration of 5'-DFUR."( [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990
)
0.28
" At the end of perfusion alpha-fluoro-beta-alanine comprised 90 to 95% of FUDR-derived total radioactivity in the tissue even at initially 2400 microM FUDR, although at this FUDR dosage 20% of the substrate remained unmetabolized in the medium."( Nonlinear elimination kinetics of 5-fluoro-2'-deoxyuridine in isolated perfused rat liver and isolated hepatocytes.
Foth, H; Kahl, GF; Kunellis, EM; Müseler, T, 1990
)
0.28
"5'-DFUR was administered orally at 800 mg/day, for total dosage of 57."( [A resected case of gastric carcinoma with complete remission of Virchow's node metastasis by 5'-DFUR administration].
Fukuda, H; Kitahara, T; Nagamine, H; Nakaguchi, K; Nakano, Y; Onoe, K, 1990
)
0.28
"2 mg/kg/day, and adoption of a policy of early dosage reduction, treatment interruption, or termination of therapy for persistent elevations in alkaline phosphatase, only two further cases of serious biliary toxicity occurred."( A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
Acord, P; Friedman, MA; Hannigan, JF; Hohn, DC; Ignoffo, RJ; Lewis, BJ; Rayner, A; Stagg, RJ, 1989
)
0.51
"The object of this study was to develop a sustained release implantable dosage form of a new silicone gel (PHYCON 6600R) which undergoes addition polymerization to produce a solid gel at ordinary temperature."( Application of new silicone gel to sustained release dosage form of antitumor drug.
Azuma, T; Imasaka, K; Kawaguchi, T; Nagai, T; Ueda, H, 1989
)
0.28
" The optimal dosage for a phase II study was suggested to be less than 2,100 mg/body/day."( [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Furue, H; Kanamaru, R; Kimura, K; Komita, T; Murakami, M; Nakao, I; Ohta, K; Saito, T; Wakui, A; Yokoyama, M, 1985
)
0.27
" The optimal daily dosage was considered to be 800-1,200 mg/body/day."( [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985
)
0.27
" The oral daily dosage of 5'-DFUR was 1,200 mg and that of tegafur was 800 mg, both drugs being administered every day for more than 4 weeks."( [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985
)
0.27
"1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug."( [Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985
)
0.27
"5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day."( [Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients].
Imamura, Y; Irie, K; Nakamura, T; Suehiro, I; Yasutake, K; Yoshida, M; Yoshimura, Y, 1985
)
0.27
" The authors suggest investigation of an alternate drug schedule and/or dosage of floxuridine to eliminate or minimize this serious complication."( Fibrosis of extrahepatic biliary system after continuous hepatic artery infusion of floxuridine through an implantable pump (Infusaid pump).
Gourley, WK; Haq, MM; Peterson, DF; Valdes, LG, 1986
)
0.72
" At an optimum dosage level of 40 mg/kg, 7 and 8 produced 90% and 60% "cures" (greater than 60-day survivors), respectively."( Antineoplastic activity of 3'-(chloroethyl)nitrosourea analogues of 2'-deoxyuridine and 2'-deoxy-5-fluorouridine.
Brubaker, WF; Lin, TS; Park, S; Prusoff, WH; Wang, ZH, 1986
)
0.27
" The neurotoxicity was dose related, affecting 7 of 8 patients in the high dosage group and 3 of 9 patients in the low dosage group."( Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5'-dFUrd).
Fosså, SD; Heier, MS, 1986
)
0.27
" Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index."( Phase II clinical evaluation of doxifluridine.
Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986
)
0.27
" In 10 of these tumors, comparative dose-response curves were obtained."( Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA).
Flentje, D; Flentje, M; Schlag, P, 1986
)
0.27
" In tumor tissue, optimal doses of FUra or FdUrd resulted in lower (a) FdUMP levels (5- to 2-fold), (b) RNA-level antimetabolites (6- to 3-fold), and (c) DNA-level antimetabolites (10- to 4-fold) compared to an optimal dosage of FdCyd plus H4Urd."( Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman, DA; Briggle, TV; Greer, S, 1987
)
0.27
"Cells of a suspension HeLa culture at the logarithmic phase of growth were exposed to 60Co-gamma-rays (5 Gy), incubated in the nutritious medium, and in 4 h subjected to repeated irradiation: the dose-response function and the dynamics of DNA synthesis inhibition were determined."( [Gamma-irradiation induces in HeLa cells radioresistant DNA synthesis].
Aminev, AG; Konstantinova, SA; Saenko, AS; Synzynys, BI,
)
0.13
" This diarrhea, however, disappeared rapidly by decreasing the dosage or termination of treatment."( [A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Tsukagoshi, S, 1987
)
0.27
" The cytostatic effect of cytosine arabinoside (ara-C) prodrug liposomes against L1210 leukemia showed to be superior to free ara-C treatment in respect to drug dosage and treatment schedule."( [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
Hartmann, HR; Hengartner, H; Rubas, W; Schott, H; Schwendener, RA; Supersaxo, A, 1987
)
0.27
"To investigate the optimal dosage schedule for 5'-deoxy-5-fluorouridine (5'-DFUR), a randomized comparative study was performed in patients with inoperable or advanced gastric cancer."( [Randomized comparison of continuous and intermittent oral administration of 5'-deoxy-5-fluorouridine in the treatment of advanced gastric cancer; a phase II trial by the Multi-institutional Cooperative Study Group].
Hasegawa, K; Hatta, Y; Kawachi, M; Kurihara, M; Niitani, H; Suwa, T; Taguchi, S; Tsuboi, E; Yasui, A; Yoshimori, K, 1987
)
0.27
" These dose-response data indicate that locally recurrent tumors are frequently, but not always, different from the original primary tumor in response to chemotherapy agents and ionizing X-irradiation."( Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation.
Aeed, PA; Estrada, J; Welch, DR, 1988
)
0.27
"5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks."( [Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
Komaki, K; Konishi, Y; Miki, H; Monden, Y; Morimoto, T; Ooshimo, K; Tanaka, T; Uomine, Y; Yamakawa, T, 1988
)
0.27
" The frequency of cerebellopathy may depend on the dosage and type of administration of the drug."( Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine.
Fosså, SD; Heier, MS, 1985
)
0.27
" 5'-DFUR was administered three or four times a day at a daily dosage of 600 to 1200 mg."( [Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group].
Gocho, Y; Ishitani, K; Kogo, Y; Kouda, K; Koyama, R; Matsuda, M; Nagai, T; Niitsu, Y; Saijo, N; Urushizaki, I, 1985
)
0.27
" 5'-DFUR (5'-deoxy-5-fluorouridine) was administered orally at 1,200 mg/day for 23 weeks, for a total dosage of 110."( [A case of gastric cancer in which long-term administration of 5'-deoxy-5-fluorouridine (5'-DFUR) proved effective].
Iwao, N; Koda, T; Kurahori, T; Miyaji, J; Okahisa, N; Sonoda, T; Sumi, S; Yanagimoto, H, 1987
)
0.27
" Dose-response studies indicated that a single AAV particle and a single infectious Ad."( Immunofluorescent studies of the potentiation of an adenovirus-associated virus by adenovirus 7.
Blacklow, NR; Hoggan, MD; Rowe, WP, 1967
)
0.25
" Fibroblast cultures from 10 retarded males expressed fra(X) in a dose-response relationship to increasing concentrations of FUdR."( Cytogenetic investigations in mentally retarded and normal males from 14 families with the fragile site at Xq28. Results of folic acid treatment on fra(X) expression.
Nielsen, KB; Tommerup, N, 1984
)
0.27
" Dose-response curves and survival parameters were calculated for local tumor-derived clones MTC and MTF7 and lung metastasis-derived clone MTLn3."( Phenotypic drift and heterogeneity in response of metastatic mammary adenocarcinoma cell clones to adriamycin, 5-fluoro-2'-deoxyuridine and methotrexate treatment in vitro.
Nicolson, GL; Welch, DR,
)
0.13
" 5'-dFUrd was a more effective antitumor agent and was less toxic over a wide dosage range (50 to 400 mg/kg) than the other agents tested as measured by: (a) the ability to prevent gross development of inoculated tumor; (b) 45-day survival; and (c) weight change over the treatment period."( Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.
Armstrong, RD; Diasio, RB, 1980
)
0.26
" At the 1st hr after dosing the 5-FU level in the small intestine was close to, but that in other tissues was much lower than, the 5-FU level in the tumor of both types."( Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.
Fukazawa, H; Hongu, Y; Ichihara, S; Shimizu, H; Suzuki, S, 1980
)
0.26
"Double dosing and single sampling seems to be the simplest and most reliable method for detecting clastogens in the mouse peripheral blood micronucleus test."( An optimal, generalized sampling time of 30 +/- 6 h after double dosing in the mouse peripheral blood micronucleus test.
Higashikuni, N; Sutou, S, 1995
)
0.29
" The current phase I study was designed to determine the pharmacokinetic profiles and clinical tolerance of escalating doses of the pure biologically active S-isomer of leucovorin ((S)-LV) given IP with the same dosing schedule of FUDR."( Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.
Chan, KK; Israel, VK; Jeffers, S; Jiang, C; Leichman, CG; Leichman, L; Morrow, CP; Muggia, FM; Roman, L; Tulpule, A, 1995
)
0.29
" As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats."( [Chrono-chemotherapy and dose intensity].
Lévi, F, 1995
)
0.29
" Eleven out of 19 patients (58%; 95% CI:34-80%) showed a complete (2 cases) or partial (9 cases) response to this treatment, regardless of the 5dFUR dosage employed."( Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and L-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
Biglietto, M; Carteni, G; Catalano, G; Comella, G; Comella, P; Della Vittoria Scarpati, M; Palmieri, G; Pandolfi, A; Stampino, CG,
)
0.13
"Suramin was administered as a 6-day continuous infusion every week for 8 consecutive weeks by using a computer-assisted dosing of Bayesan pharmacokinetics to maintain suramin plasma concentrations of 200-250 micrograms/ml."( Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995
)
0.29
" Administered intraperitoneally at optimal dosage for 5 consecutive days, PIV2FdUMP and PIV2 3'-O-Ac-FdUMP were as effective as FU at prolonging the life spans of mice bearing intraperitoneally implanted P388 leukemia."( Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
Farquhar, D; Khan, S; Saunders, PP; Srivastva, DN, 1994
)
0.29
" The dose-response curve was steep, with 3/3 patients treated at a dose of 1,750 mg/m2 developing grade IV diarrhea."( Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.
Creaven, PJ; Frank, C; Levine, EG; Meropol, NJ; Petrelli, NJ; Proefrock, A; Raghavan, D; Rodriguez-Bigas, M; Rustum, YM; Udvary-Nagy, S, 1994
)
0.55
"The treatment with 5'-dFUR was stopped at 5 g/m2, since this level corresponded to the maximum monthly dosage reported in the literature (36-38 g)."( A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Antimi, M; Majoli, L; Minelli, M; Pandolfi, A; Papa, G; Stampino, CG, 1993
)
0.29
" Although the MTD was not reached, it can be stated that the dosage administered in this study could be explored in a larger trial."( A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Antimi, M; Majoli, L; Minelli, M; Pandolfi, A; Papa, G; Stampino, CG, 1993
)
0.29
" Dose-response experiments analyzing the dependence of cell death on drug concentration indicated a marked resistance of BAF3bcl-2 to FDUR treatment."( Bcl-2 oncogene protects a bone marrow-derived pre-B-cell line from 5'-fluor,2'-deoxyuridine-induced apoptosis.
Collins, MK; López-Rivas, A; Marvel, J; Oliver, FJ, 1993
)
0.29
" We explored this strategy by quantitating the synergy produced by combinations of acyclovir and other drugs using three-dimensional dose-response surface methodology (MacSynergy II)."( Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir.
Prichard, LE; Prichard, MN; Shipman, C, 1993
)
0.29
" In terms of ER stratification, ER(-) patients in the dosing groups showed increasing tendencies in S-phase and significant differences of G1- as well as G2+M phases."( [Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer].
Fujii, A; Hamano, K; Kamio, T; Katoh, T; Kimura, T; Muraki, H; Yamamoto, K, 1993
)
0.29
" Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug."( Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations.
Lackman, RD; Weiss, AJ, 1997
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.31
" Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies."( [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Monden, T; Tono, T, 2000
)
0.31
" The combination showed better antitumor efficacy than the monotherapy of either agent in either dosing regimen."( Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001
)
0.31
" It was repeated every 3 weeks, as long as possible, including dosage levels of 5 scheduled steps."( [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001
)
0.31
" The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively."( Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Higashigawa, M; Kagawa, Y; Kakito, H; Kawasaki, H; Kojima, M; Ohkubo, T; Ooi, A; Sakurai, M, 2001
)
0.31
" Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day."( [A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].
Otsuka, T; Tashiro, S; Terashima, Y, 2002
)
0.31
" Although the CDDP dosage had been reduced to 5 mg/week 1 year previously, the tumor was still reducing in size in November 2000."( Metastatic urothelial cancer showing an efficacy by low-dose cisplatin.
Hirata, H; Matsuyama, H; Yamakawa, G, 2002
)
0.31
" Rats were dosed intravenously with either 2'-fluorouridine (2'-FU) or 2'-fluorocytidine (2'-FC) at doses of 5, 50, and 500 mg/kg/day for 90 days."( Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS.
Bendele, RA; Koc, H; Lehrman, SR; Richardson, FC; Richardson, KA; Swenberg, JA; Zhang, C, 2002
)
0.31
" Overall, our results demonstrate that there is no gene dosage effect in the chloroplast and that transcript abundance is not limiting in the expression of chloroplast-encoded protein."( Searching limiting steps in the expression of chloroplast-encoded proteins: relations between gene copy number, transcription, transcript abundance and translation rate in the chloroplast of Chlamydomonas reinhardtii.
Drapier, D; Eberhard, S; Wollman, FA, 2002
)
0.31
" Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery."( [One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002
)
0.31
" The present results have no clinical implications for the use of capecitabine and argue against the value of therapeutic drug monitoring for dosage adjustment."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" The anti-tumor effective dosage of P5, P6 and their mixture, P5+P6, were obtained in dose-dependent manner."( Therapeutic effects of novel anti-tumor reagent, apoptosis inducing nucleosides from CD57+HLA-DRbright natural suppressor cell line on human gastric carcinoma-bearing SCID mice.
Guo, M; Jin, A; Mori, E; Mori, T; Qi, Y; Takasaki, S, 2004
)
0.32
" Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition."( A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004
)
0.32
"First, we determined the optimal dosing regimen in murine models."( Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005
)
0.33
" A further six patients were added in order to confirm the safety of this dosage level, and no more DLTs except for grade 3 nausea in one patient were observed in the second cohort."( A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
Endo, S; Hidaka, S; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T, 2005
)
0.33
" The mean dosage per course of TXT was 58."( [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005
)
0.33
" The significance of treatment dosage and duration was obvious when 5-DFUR and Tam cotreatment was observed to be antagonistic in 3-day cultures of a second MCF-7 subline and T47D cells."( Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells.
Bollig, A; Du, QQ; Fan, ST; Liao, J; Sarkar, FH; Yu, B, 2005
)
0.33
" Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment."( Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Lokiec, F; Rezaí, K; Urien, S, 2005
)
0.33
" These data can be used to rationally design gemcitabine dosage regimes for canine oncology patients and as a basis for future investigations on the in vivo intracellular accumulation of gemcitabine triphosphate in dogs."( Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
Freise, KJ; Martín-Jiménez, T, 2006
)
0.33
" Fixing synergistic drug ratios in pharmaceutical carriers provides an avenue by which anticancer drug combinations can be optimized prospectively for maximum therapeutic activity during preclinical development and differs from current practice in which dosing regimens are developed empirically in late-stage clinical trials based on tolerability."( Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG, 2006
)
0.33
" A sensitive analytical method for the quantitation of gemcitabine is required for the assessment of alternative dosage and treatment schemes."( Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.
Cerny, T; Früh, M; Lanz, C; Lauterburg, BH; Thormann, W, 2007
)
0.34
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" This is the first clinical evaluation of fixed drug ratio dosing designed to maintain synergistic molar ratios for enhanced therapeutic benefit."( Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Batist, G; Chi, KN; Chia, SK; Gelmon, KA; Janoff, AS; Louie, AC; Mayer, LD; Miller, WH; Swenson, CE, 2009
)
0.35
" Dose-response relationships of skeleton variations and malformations induced by three antineoplastic drugs (FUDR: 5-fluoro-2'-deoxyuridine, HU: hydroxyurea and 6-MPr: 6-mercaptopurine-riboside) were evaluated."( Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment.
Chahoud, I; Paumgartten, FJ, 2009
)
0.35
" Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.36
"To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.36
"Pancreatic ductal adenocarcinoma tumour tissue from genetically engineered mouse models of pancreatic cancer (KP ( FL/FL ) C and KP ( R172H/+) C) was collected after dosing the mice with gemcitabine."( A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
Bapiro, TE; Cook, N; Frese, KK; Goldgraben, MA; Griffiths, JR; Jacobetz, MA; Jodrell, DI; Madhu, B; Olive, KP; Richards, FM; Smith, DM; Tuveson, DA, 2011
)
0.37
"To develop and internally validate a population pharmacokinetic model for gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU); and to evaluate its predictive perfomance for personalizing the dosage used in cancer patients."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
"The population pharmacokinetic model adequately characterised the gemcitabine and dFdU plasma concentrations in the study population over time, and can be used to accurately and precisely optimise gemcitabine dosing regimens in cancer patients."( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B,
)
0.13
" The high bioavailability (~90%) following oral dosing with RFUdR indicates that this DAMM prodrug may be suitable for oral dosing to deliver FUdR and RA for cancer chemotherapy."( Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice.
Knaus, EE; Wiebe, LI; Xia, Z, 2013
)
0.39
" Because of its amphiphilic nature, the CPT-FUDR conjugate self-assembled into stable nanoparticles which could simultaneously release fixed dosage of the two drugs in cancer cells."( Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.
Hu, M; Huang, P; Su, Y; Wang, Y; Yan, D; Zhou, L; Zhu, X, 2015
)
0.66
" Medical oncology experience in floxuridine dosing is critical in maximizing the treatment doses and the number of cycles administered while avoiding biliary toxicity."( Starting a successful hepatic artery infusion pump program: A practical guide.
Barry-Hundeyin, M; Cavnar, MJ; Ellis, CS; Gholami, S; Kim, J; McDonald, HG; Pandalai, PK; Patel, RA, 2023
)
1.19
" Isobologram models, zero interaction potency dose-response surface plots and matrices were generated to evaluate the combination synergism of the two drugs."( Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles.
Gupta, U; Hira, SK; Manna, PP; Paladhi, A; Singh, R; Singh, RA; Srivastava, DN; Srivastava, P, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
radiosensitizing agentA drug that makes increases the sensitivity of tumour cells to radiation therapy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency0.55370.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency12.95790.000221.22318,912.5098AID743036; AID743040; AID743053
thioredoxin glutathione reductaseSchistosoma mansoniPotency35.48130.100022.9075100.0000AID485364
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.03610.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.08100.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency13.31110.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency13.21990.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.71570.000229.305416,493.5996AID743069; AID743078; AID743080
67.9K proteinVaccinia virusPotency1.00000.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency0.46110.005210.865235.4813AID686970
Histone H2A.xCricetulus griseus (Chinese hamster)Potency1.02470.039147.5451146.8240AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.58050.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.77970.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.33490.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.07310.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.05370.005612.367736.1254AID624032; AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.17960.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency1.17810.002319.595674.0614AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.63100.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/nucleoside cotransporter 2Homo sapiens (human)IC50 (µMol)1,000.00005.50005.50005.5000AID1205658
Thymidylate synthaseMus musculus (house mouse)IC50 (µMol)5.93100.00041.322610.0000AID212496; AID212498; AID212499; AID212635; AID212644; AID212645; AID212646; AID212647; AID589980; AID589981; AID589982; AID589983; AID589984; AID589985
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)12,210.00000.18000.19000.2000AID1675907
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)0.68900.06008.9128130.5170AID1902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC500.34600.128015.173038.6100AID1259420
Thymidine phosphorylaseHomo sapiens (human)Km631.00000.16000.16000.1600AID211066
Thymidine kinaseVaccinia virus WRKm113.00004.30004.30004.3000AID324741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (156)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processSodium/nucleoside cotransporter 2Homo sapiens (human)
xenobiotic metabolic processSodium/nucleoside cotransporter 2Homo sapiens (human)
neurotransmitter transportSodium/nucleoside cotransporter 2Homo sapiens (human)
xenobiotic transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
pyrimidine nucleobase transportSodium/nucleoside cotransporter 2Homo sapiens (human)
purine nucleoside transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
uridine transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
adenosine transportSodium/nucleoside cotransporter 2Homo sapiens (human)
inosine transportSodium/nucleoside cotransporter 2Homo sapiens (human)
azole transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
pyrimidine-containing compound transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
transport across blood-brain barrierSodium/nucleoside cotransporter 2Homo sapiens (human)
nucleoside transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
purine nucleobase transmembrane transportSodium/nucleoside cotransporter 2Homo sapiens (human)
retina homeostasisSodium/nucleoside cotransporter 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (49)

Processvia Protein(s)Taxonomy
neurotransmitter transmembrane transporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
purine nucleobase transmembrane transporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
nucleoside:sodium symporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
purine nucleoside transmembrane transporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
uridine transmembrane transporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
azole transmembrane transporter activitySodium/nucleoside cotransporter 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
vesicle membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
apicolateral plasma membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
coated vesicleSodium/nucleoside cotransporter 2Homo sapiens (human)
brush border membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
plasma membraneSodium/nucleoside cotransporter 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (616)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID99531In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID201738Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 200 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID704514Stability of the compound in potassium phosphate buffer at pH 7.4 assessed as E.coli thymidine phosphorylase-mediated release of 5-FU after 5 mins by [19F] NMR spectroscopy2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID516596Anticancer activity against human ACHN cells by SRB assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.
AID1199997Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID124350Average weight change in treated P388 leukemia mice to that of control mice on administration of 100 mg/kg of compound in a q. d. 1-9 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID704521Ratio of IC50 for thymidine-kinase deficient human HeLa cells to IC50 for human HeLa cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID452040Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID704507Ratio of IC50 for ENT1 transporter-deficient human CEM cells to IC50 for human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID451858Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1199998Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1675941Ratio of AUC (0 to t) in NOD SCID nude mouse plasma xenografted with ZR-75-1 cells to AUC (0 to t) in NOD SCID mouse tumour xenografted with ZR-75-1 cells
AID1199982Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1205659Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake at 100 uM in presence of Na+ by liquid scintillation counting method2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.
AID677479Cytotoxicity against human A549 cells after 72 hrs by microplate reader method2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID130344The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1200007Antimicrobial activity against methicillin-resistant Staphylococcus aureus 573/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1135478Antiviral activity against Vaccinia virus infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID133754The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1675909Drug uptake in MDCK cells incubated for 10 mins by HPLC analysis
AID1294504Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID1135810Cytotoxicity against mouse S180 cells at 0.001 uM after 18 to 42 hrs relative to control1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1292260Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1293746Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human T98G cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID589990Antiviral activity against Human coxsackievirus B4 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID99515Inhibitory concentration of compound rwas calculated on L5178Y cells by [3H]Thd incorporation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID118986Median life span of the treated P388 leukemia mice to that of control mice after intraperitoneal administration of 600 mg/kg of compound in a q.d. 1-5 schedule; 13.1/12.01981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID115002Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia sensitive cells compared with controls at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1199995Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID3371Inhibitory concentration was calculated on 3T3 cells by using growth assay1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID452063Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675924Antiproliferative activity against human MIA-PaCa-2 cells assessed as growth inhibition after 24 hrs by MTT assay
AID101237The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -6)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID116940Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID231619Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 100 mg/kg, ip; 18/241980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID119489Number of deaths recorded in mice with P388 leukemia on days 1-5 after intraperitoneal administration of 400 mg/kg of compound in a q.d. 1-5 schedule; 0/61981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1293741Antiproliferative activity against human U87MG cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID212644Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID671045Cytotoxicity against thymidine kinase-deficient mouse LMTK cells after 5 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and study of cyclic pronucleotides of 5-fluoro-2'-deoxyuridine.
AID1304898AUC (infinity) in Sprague-Dawley rat plasma assessed as FdUMP formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID116942Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID452062Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1304906Cmax in Sprague-Dawley rat liver assessed as 5-FU formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID1186256Retention time of the compound treated with FU'U ODN by HPLC analysis2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner.
AID1675921Half life of compound in human MIA PaCa-2 cell homogenate
AID589981Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 4 hrs by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID101239The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 5*(10e -5)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID2904In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID452043Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID704509Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1293742Antiproliferative activity against human MRC5 cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID3370Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID517843Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication relative to control2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID342001Antimicrobial activity against Streptococcus pyogenes AP1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID98529Evaluation of antitumor activity against mutant murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID527281Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID125495Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (Molt4/C8)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID114995Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID452069Anticancer activity against human MDA-N cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99514Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition)1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates.
AID452046Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99518Inhibitory concentration of compound was calculated on L5178Y cells by using growth assay1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID96655Dose inhibiting L1210/0 murine leukemia cell proliferation by 50%1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID1675904Substrate activity at SLC6A14 (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glycine uptake incubated for 10 mins by HPLC/MS/MS analysis
AID1589118Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID704506Ratio of IC50 for human CEM cells expressing human ENT1 transporter in presence of dipyridamole to IC50 for human CEM cells expressing human ENT1 transporter2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID212645Thymidylate synthase inhibition in thymidine kinase deficient /TK cells after 2 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID597791Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
AID1304891AUC (infinity) in Sprague-Dawley rat liver assessed as FDUR formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID1404380Antiparasitic activity against Cryptosporidium parvum BGF infected in human HCT8 cells incubated for 48 hrs by FITC/DAPI staining based fluorescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID704517Ratio of 5-FU IC50 to compound IC50 for human HeLa cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1200004Antimicrobial activity against methicillin-resistant Staphylococcus aureus 522/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID156524Concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary Rabbit by 50%1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and antiviral activity of 5-[(cyanomethylene)oxy]-2'-deoxyuridine.
AID597793Cytotoxicity against mouse RAW264.7 cells after 24 hrs by resazurin assay2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
AID326169Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID1304887Cmax in Sprague-Dawley rat plasma assessed as FdUMP formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID1200017Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 470/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID201739Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 25 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID452048Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675923Antiproliferative activity against human ZR-75-1 cells assessed as growth inhibition after 24 hrs by MTT assay
AID589863Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1293745Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human T47D cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID1675905Substrate activity at SLC6A14 (unknown origin) expressed in Xenopus laevis oocytes assessed as ABT0+ mediated drug uptake at 0.5 mM incubated for 10 mins by HPLC analysis
AID3369Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID704527Cytostatic activity against mouse L1210/0 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID124353Average weight change in treated P388 leukemia mice to that of control mice on administration of 50 mg/kg of compound in a q. d. 1-9 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1199977Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID315586Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.
AID451857Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1200001Antimicrobial activity against methicillin-resistant Staphylococcus aureus 456/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID589991Antiviral activity against Human coxsackievirus B4 infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID133610The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/0 Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID516598Anticancer activity against human PC3 cells by SRB assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.
AID326171Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID451877Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1131071Toxicity in mouse in po dosed CD1 mouse assessed as leukopenia administered once daily starting shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID324741Activity of Vaccinia virus WR thymidine kinase assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID589984Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 4 hrs by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID89821Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
AID119488Number of deaths recorded in mice with P388 leukemia on days 1-5 after intraperitoneal administration of 200 mg/kg of compound in a q.d. 1-5 schedule; 0/61981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID452047Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID96471Growth inhibition in L1210 mouse leukemia cells after 2 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID1216044Activity at MRP5 in human Colo-357 cells assessed as 5-FdUMP accumulation at 100 uM after 15 mins in presence of MRP inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID212647Thymidylate synthase inhibition in wild type LM cells after 2 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID647761Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
AID99516Inhibitory concentration of compound was calculated on L5178Y cells by [14C]Leu incorporation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID1675906Drug uptake in Xenopus laevis oocytes at 0.5 mM incubated for 10 mins by HPLC analysis
AID116959Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID232840Ratio of Vmax to that of dThd (Vmax = 0.14)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID96659Dose inhibiting L1210/Br-dUrd murine leukemia cell proliferation by 50%1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID589878Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1131495Cytotoxicity against mouse S180 cells at 0.1 uM after 18 to 42 hrs relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID1200003Antimicrobial activity against methicillin-resistant Staphylococcus aureus 514/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID301375Cytostatic activity against human HT1080 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Cytostatic evaluations of nucleoside analogs related to unnatural base pairs for a genetic expansion system.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1594190Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID1294502Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID1813512Cytotoxicity against human A549 cells after 48 hrs measured by MTT assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
AID116955Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID704510Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1200009Antimicrobial activity against methicillin-resistant Staphylococcus aureus 586/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID46639Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID704508Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1200002Antimicrobial activity against methicillin-resistant Staphylococcus aureus 462/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID211066Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID1589123Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human HeLa cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID201737Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 100 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1294503Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID1200000Antimicrobial activity against methicillin-resistant Staphylococcus aureus 452/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1131482Antiviral activity against HSV1 CL101 infected in African green monkey Vero cells assessed as plaque forming unit at 400 uM after 40 hrs relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID451863Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID101240The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -6)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID46626In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line (CEM-TK)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID122435Life span ratio of P388 leukemia mice treated to that of control mice at dose 600 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID130335The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1199981Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID342000Antimicrobial activity against Staphylococcus aureus CCM 885 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID452064Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID2909In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1292265Selectivity index, ratio of IC50 for HDF cells to IC50 for human HepG2 cells2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID233950Ratio of GI50 without hPAP/ GI50 with hPAP2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates.
AID1398358Cytotoxicity against human HepG2 cells at 1.5 to 200 uM after 72 hrs by WST1 assay2018Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15
Studies directed toward the asialoglycoprotein receptor mediated delivery of 5-fluoro-2'-deoxyuridine for hepatocellular carcinoma.
AID1293737Antiproliferative activity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID124994Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1135811Antimicrobial activity against Streptococcus faecium assessed as growth inhibition at 400 uM after 15 to 17 hrs by turbidity assay in presence of 7 uM deoxythymidine1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID119487Number of deaths recorded in mice with P388 leukemia on days 1-5 after intraperitoneal administration of 100 mg/kg of compound in a q.d. 1-9 schedule; 0/61981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1131488Cytotoxicity against African green monkey Vero cells at 0.1 uM after 3 days by haemocytometry1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID1199999Antimicrobial activity against Staphylococcus epidermidis ATCC 35984 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID372372Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID44010In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates.
AID527285Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID1589119Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID99532In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID452056Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID209964Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Synthesis of 2'-deoxyuridine and 5-fluoro-2'-deoxyuridine derivatives and evaluation in antibody targeting studies.
AID130487The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID96472Growth inhibition in L1210 mouse leukemia cells after 24 h treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID119486Number of deaths recorded in mice with L-1210 leukemia on days 1-5 after intraperitoneal administration of 100 mg/kg of compound in a q.d. 1-9 schedule; 0/61981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID139154The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID212635Inhibition of cellular thymidylate synthase activity of murine leukemia cell line (L1210) in permeabilised cells.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID124352Average weight change in treated P388 leukemia mice to that of control mice on administration of 400 mg/kg of compound in a q. d. 1-5 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1200016Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 469/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1304893AUC (infinity) in Sprague-Dawley rat plasma assessed as FDUR formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID452061Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1404381Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.
AID704512Ratio of IC50 for Mycoplasma hyorhinis-infected mouse L1210 cells to IC50 for mouse L1210/0 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID44009In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates.
AID1293739Antiproliferative activity against human T98G cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID122618Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1200008Antimicrobial activity against methicillin-resistant Staphylococcus aureus 585/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID589883Cytostatic activity against human HeLa cells in presence of 500 uM uracil2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID96474Growth inhibition in L1210 mouse leukemia cells after 8 h treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID1293748Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human U87MG cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID452059Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675933Antitumour activity against human MDA-MB-231 cells xenografted in NOD SCID nude mouse assessed as tumour inhibition at 90 mg/kg, iv administered for 20 days measured every 2 day by caliper method relative to control
AID43836Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119)2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Covalent analogues of DNA base-pairs and triplets. Part 2: synthesis and cytostatic activity of bis(purin-6-yl)acetylenes,-diacetylenes and related compounds.
AID53752Compound was tested for its ability to inhibit growth of Escherichia coli DH5 alpha cells at 100 uM concentration; complete arrest of cell growth observed1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
A photoactivated prodrug.
AID1594188Selectivity ratio of IC50 for human MDA-MB-468 cells under aerobic condition to IC50 for human MDA-MB-468 cells under hypoxic condition2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID229757Ratio of ID50 for L1210/0 cell growth and ID50 for L1210/BdUrd cell growth.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID1135481Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID122432Life span ratio of P388 leukemia mice treated to that of control mice at dose 200 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID116946Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1589125Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human A549 cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID671044Cytotoxicity against human A2780 cells after 5 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Synthesis and study of cyclic pronucleotides of 5-fluoro-2'-deoxyuridine.
AID452042Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1594193Selectivity ratio of IC50 for human SW620 cells under aerobic condition to IC50 for human SW620 cells under hypoxic condition2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID1813515Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
AID1200019Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 489/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1293749Apparent permeability in human Caco2 cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID1292261Cytotoxicity against HDF cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1293744Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human Caco2 cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID1589126Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human U87 cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID133742The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/0 Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1292267Cytotoxicity against human 143B cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID118984Median life span of the treated P388 leukemia mice to that of control mice after intraperitoneal administration of 400 mg/kg of compound in a q.d. 1-5 schedule; 14.3/11.91981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID72041Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID704522Ratio of IC50 for thymidine-kinase deficient mouse L1210 cells to IC50 for mouse L1210/0 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1199989Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HT-29 cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID597721Binding affinity to 7 gram of hydroxyapatite at 246 mg after 24 hrs by UV-spectrophotometer analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
AID156526Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [Me-3H]-dThd1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and antiviral activity of 5-[(cyanomethylene)oxy]-2'-deoxyuridine.
AID1135817Retention time of the compound by liquid chromatography1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID455568Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and antitumor activity of novel 2',3'-dideoxy-2',3'-diethanethionucleosides bearing 1,2,3-triazole residues.
AID589880Cytostatic activity against human HeLa cells in presence of 20 uM thymidine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID769616Cytotoxicity against human HeLa cells after 72 hrs by SRB assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity.
AID212496Inhibition of cellular thymidylate synthase activity of mouse fibroblast (L929 TK-) in intact cells.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID1632122Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID1131072Toxicity in mouse in po dosed CD1 mouse assessed as change in body weight administered once daily starting shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID1292258Cytotoxicity against human KB cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID133745The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1675920Half life of compound in human ZR-75-1 cell homogenate
AID101238The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -7)Mconc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID341997Antimicrobial activity against Streptococcus sp. 07706-1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID3368Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID82529Evaluated for cytotoxic concentration required to reduce normal human embryonic lung (fibroblast) (HEL) cell growth by 50%; No data2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID1200012Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 461/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1404379Cytotoxicity against human HCT8 cells2018Journal of natural products, 04-27, Volume: 81, Issue:4
Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.
AID211811Compound was tested for its inhibition against Thymidylate synthase up to concentration of 1 mM; IA means inactive1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates.
AID704513Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID154359Average days survival of female CDF1 mice bearing lymphocytic leukemia, when 10 E-6 tumor cells were injected intraperitoneally, dosed for 9 days at 20 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID372375Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID1200010Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 459/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID99533In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID1199987Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID451855Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID455566Cytotoxicity against human A549 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and antitumor activity of novel 2',3'-dideoxy-2',3'-diethanethionucleosides bearing 1,2,3-triazole residues.
AID234496Ratio of Concentration of intact versus pearmeabilized of above1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID96829Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID118982Median life span of the treated P388 leukemia mice to that of control mice after intraperitoneal administration of 100 mg/kg of compound in a q.d. 1-9 schedule; 11.4/11.31981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID106146Evaluated for cytotoxicity against murine embryo fibroblasts (MEF)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID451879Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID324743Activity of human thymidine kinase 1 assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID1589117Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID133612The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/0 Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1292264Selectivity index, ratio of IC50 for HDF cells to IC50 for human MCF7 cells2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID99069Tested in vitro for the inhibition of cell growth of mouse leukemia L1210 cell (ATCC CCL 219)2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Covalent analogues of DNA base-pairs and triplets. Part 2: synthesis and cytostatic activity of bis(purin-6-yl)acetylenes,-diacetylenes and related compounds.
AID8233Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Synthesis of 2'-deoxyuridine and 5-fluoro-2'-deoxyuridine derivatives and evaluation in antibody targeting studies.
AID1199993Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1292257Cytotoxicity against human HeLa cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID248687Inhibitory concentration required to reduce cellular survival to 50% towards murine tumor EMT6/KU cell line2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
AID704511Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1199994Antimicrobial activity against Staphylococcus aureus ACTC 4163 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID589865Antiviral activity against Herpes simplex virus type-2 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID341999Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1200005Antimicrobial activity against methicillin-resistant Staphylococcus aureus 537/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1632131Selectivity index, ratio of IC50 for HDF to IC50 for human HepG2 cells2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID452071Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99649In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Leu.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID1293738Antiproliferative activity against human T47D cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID451864Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID527283Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID1199980Antiproliferative activity against human doxorubicin-resistant LoVo/DX cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1135815Competitive inhibition of HSV-1 pyrimidine deoxythymidine kinase using 2-[14C]deoxythymidine as substrate1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID124354Average weight change in treated P388 leukemia mice to that of control mice on administration of 600 mg/kg of compound in a q. d. 1-5 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID480670Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
AID451862Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID89089Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1199988Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/DX cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1594185Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID67595In vitro cell cytotoxicity against EMT-6 cell lines2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID451876Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID101236The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -5)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID115004Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia sensitive cells compared with controls at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID451865Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1131496Cytotoxicity against mouse S180 cells at 0.01 after 18 to 42 hrs relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID704526Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID589988Antiviral activity against Respiratory syncytial virus infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID98136In vitro concentration required for 50% inhibition (IC50) of growth of L1210 mouse leukemia cells in culture.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
Synthesis and biological activity of 5-fluoro-2',3'-dideoxy-3'-fluorouridine and its 5'-phosphate.
AID117348Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 150 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID124992Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID229760Ratio of ID50 upon addition of dThd to the ID50 upon addition of dUrd against the L1210/0 cell proliferation.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID589982Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID451872Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID324744Ratio of Vmax to Km for human thymidine kinase 12007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID139152The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1632129Selectivity index, ratio of IC50 for HDF to IC50 for human KB cells2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID1675938AUC (0 to t) in NOD SCID nude mouse plasma xenografted with ZR-75-1 cells at 90 mg/kg, iv measured up to 24 hrs by HPLC-MS/MS analysis
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID87827Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID231618Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 50 mg/kg, ip; 16/161980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID43713In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM). 1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID451875Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID1135479Antiviral activity against Herpes simplex virus 1 infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID87735Tested in vitro for the inhibition of cell growth of human cervix carcinoma HeLa S3 cell (ATCC CCL 2.2)2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Covalent analogues of DNA base-pairs and triplets. Part 2: synthesis and cytostatic activity of bis(purin-6-yl)acetylenes,-diacetylenes and related compounds.
AID451873Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99650In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Thd.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID372374Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID1675931Antitumour activity against human ZR-75-1 cells xenografted in NOD SCID nude mouse assessed as tumour inhibition at 90 mg/kg, iv administered for 20 days measured every 2 day by caliper method relative to control
AID1292268Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID216539Evaluation of antiviral activity against Vesicular stomatitis virus.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1199992Resistance index, ratio of IC50 for human HL60/Vinc cells to IC50 for human HL60 cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID101241The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -7)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID704519Ratio of 5-FU IC50 to compound IC50 for mouse L1210/0 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID122430Life span ratio of L1210 leukemia mice treated to that of control mice at dose 100 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID451853Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1632124Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID301377Cytostatic activity against human WI38 cells MTT assay2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Cytostatic evaluations of nucleoside analogs related to unnatural base pairs for a genetic expansion system.
AID1294506Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID96826Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID1200013Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 466/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1199984Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID517842Cytotoxicity against HuH7 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1293736Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID1675919Half life of compound in thymidine phosphorylase buffer at 300 uM by HPLC analysis
AID451861Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID704528Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID326168Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID452055Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID82530Evaluated for minimum cytotoxic concentration that causes a microscopically detectable alteration of normal HEL cell morphology; No data2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID1675934Cmax in NOD SCID nude mouse plasma xenografted with ZR-75-1 cells assessed as fluorouracil at 90 mg/kg, iv measured up to 24 hrs by HPLC-MS/MS analysis
AID101244The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 5*(10e -8)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID101243The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -9)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1675925Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay
AID1589120Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID1199983Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID769614Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity.
AID451860Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID94492In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1632126Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID589876Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1589127Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human HepG2 cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID1199979Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID451868Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID315588Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.
AID101212Inhibition of L1210 leukemia cells, after exposure to compound for period of 8-9 hr1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID94494In vitro cell cytotoxicity was determined against KBALB cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID589989Antiviral activity against Sindbis virus infected in Vero cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1675936AUC (0 to t) in NOD SCID nude mouse plasma xenografted with ZR-75-1 cells assessed as fluorouracil AUC at 90 mg/kg, iv measured up to 24 hrs by HPLC-MS/MS analysis
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID85091Antiviral activity against herpes simplex virus(2) strain MS expressed as virus rating1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Carbocyclic analogues of 5-substituted uracil nucleosides: synthesis and antiviral activity.
AID1199986Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60/Vinc cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1131494Cytotoxicity against mouse S180 cells at 400 uM after 18 to 42 hrs relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID1594189Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID201884Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 12.5 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1293747Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human U118MG cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID516599Anticancer activity against human MDA-MB-231 cells by SRB assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.
AID230651Ki/Km values of L1210/0 dTMP synthase for the compound was determined.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1293740Antiproliferative activity against human U118MG cells assessed as cell viability after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID96656Dose inhibiting L1210/0 murine leukemia cell proliferation by 50% in presence of 125 ug/mL of dUrd.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID589866Antiviral activity against Herpes simplex virus type-1 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID451878Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID98532Evaluation of cytostatic activity by using antitumor assays against murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID122616Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 100 mg/kg at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID589769Antiviral activity against Human parainfluenza virus 3 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1589121Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID769615Cytotoxicity against human KB cells after 72 hrs by SRB assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity.
AID452044Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1199996Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID139472The compound was tested for change in weight for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID96825Inhibitory concentration required to reduce [14C-2]-dUrd incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID451871Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99823In vitro cytotoxicity of compounds were determined on mouse fibroblast (L929 TK-).1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID122431Life span ratio of P388 leukemia mice treated to that of control mice at dose 100 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID455565Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and antitumor activity of novel 2',3'-dideoxy-2',3'-diethanethionucleosides bearing 1,2,3-triazole residues.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID218132Evaluation of antiviral activity against Vaccinia virus1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID589864Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID99825Tested in vitro for the inhibition of cell growth of murine L929 cells (ATCC CCL 1)2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Covalent analogues of DNA base-pairs and triplets. Part 2: synthesis and cytostatic activity of bis(purin-6-yl)acetylenes,-diacetylenes and related compounds.
AID124349Average weight change in treated L1210 leukemia mice to that of control mice on administration of 100 mg/kg of compound in a q. d. 1-9 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID99152Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.
AID1675930Toxicity in NOD SCID nude mouse xenografted with human MIA PaCa-2 cells assessed as body weight at 90 mg/kg, iv for 20 days (Rvb = 28.4 +/- 2.1g)
AID704525Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1304897AUC (infinity) in Sprague-Dawley rat plasma assessed as 5-FU formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID452053Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID122433Life span ratio of P388 leukemia mice treated to that of control mice at dose 400 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1199978Antiproliferative activity against human vincristine-resistant HL60/Vinc cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID231420Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 25 mg/kg, ip; 16/161980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID341998Antimicrobial activity against Streptococcus sp. 07686-2 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID451856Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1589124Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human KB cells2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID1200011Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 460/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID115007Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia sensitive cells compared with controls at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID452041Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID704523Cytostatic activity against human HeLa cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID480669Cytotoxicity against human MCF7 cells overexpressing urokinase plasminogen activator at > 20.3 uM2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
AID589985Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID118981Median life span of the treated L1210 leukemia mice to that of control mice after intraperitoneal administration of 100 mg/kg of compound in a q.d. 1-9 schedule; 8.3/8.21981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1304927Ratio of FdUMP AUC (infinity) in Sprague-Dawley rat liver to FDUR AUC (infinity) in Sprague-Dawley rat plasma at 23.62 mg/kg administered through oral gavage2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID704524Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1675908Substrate activity at PEPT1 (unknown origin) expressed in MDCK cells assessed as PEPT1 mediated drug uptake at 0.5 mM incubated for 10 mins by HPLC analysis
AID452070Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID96658Dose inhibiting L1210/0 murine leukemia cell proliferation by 50% in presence of 5 ug/mL of dThd.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine.
AID455567Cytotoxicity against human LAC cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and antitumor activity of novel 2',3'-dideoxy-2',3'-diethanethionucleosides bearing 1,2,3-triazole residues.
AID1216043Activity at MRP5 in human Colo-357 cells assessed as 5-FdUMP accumulation at 100 uM after 15 mins2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1675911Selectivity ratio of substrate activity at PEPT1 (unknown origin) expressed in MDCK cells assessed as PEPT1 mediated drug uptake to drug uptake in MDCK cells
AID341996Antimicrobial activity against Streptococcus sp. 07941-1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID201883Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 50 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1200014Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 467/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1404382Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID87506Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain F1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID326173Cytostatic activity in human HeLa S3 cells assessed as inhibition of cell growth after 48 hrs by XTT assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID1304905Cmax in Sprague-Dawley rat liver assessed as FDUR formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID1304907Cmax in Sprague-Dawley rat liver assessed as FdUMP formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID231417Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 200 mg/kg, ip; 11/161980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID212499Inhibition of cellular thymidylate synthase activity of murine leukemia cell line (L1210) in intact cells.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID589882Cytostatic activity against human HeLa cells in presence of 500 uM uridine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID451866Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID704505Ratio of IC50 for human CEM cells expressing human ENT1 transporter in presence of NBMPR to IC50 for human CEM cells expressing human ENT1 transporter2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID1131487Cytotoxicity against African green monkey Vero cells at 400 uM after 3 days by haemocytometry1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID589983Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID452057Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID597794Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
AID212498Inhibition of cellular thymidylate synthase activity of mouse fibroblast (L929 TK-) in permeabilised cells.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID517844Antiviral activity against HBV assessed as inhibition of viral DNA replication relative to control2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID451870Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID452066Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675922Half life of compound in human MDA-MB-231 cell homogenate
AID1294505Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID87508Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain McIntyre1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID101098Inhibition of L1210 leukemia cells, after exposure to compound for period of 1 hr; Not reached1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1675937Cmax in NOD SCID nude mouse tumour xenografted with ZR-75-1 cells assessed as floxuridine; 5-fluoro-2-deoxyuridine concentration at 90 mg/kg, iv measured up to 24 hrs by HPLC-MS/MS analysis
AID589879Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID98737In vitro cytotoxicity of compounds were determined on murine leukemia cell line (L1210).1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity.
AID212646Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1304916AUC (infinity) in Sprague-Dawley rat liver assessed as 5-FU formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID589873Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID704518Ratio of 5-FU IC50 to compound IC50 for human CEM/0 cells after 72 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID451869Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID94495In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1589122Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID139474The compound was tested for change in weight for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID87826Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain 196.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1675910Selectivity ratio of substrate activity at SLC6A14 (unknown origin) expressed in Xenopus laevis oocytes assessed as ABT0+ mediated drug uptake to drug uptake in Xenopus laevis oocytes
AID452068Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID87828Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain Lyons1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID704516Ratio of IC50 for thymidine-kinase deficient human CEM cells to IC50 for human CEM/0 cells after 48 hrs by cell counting2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
AID99530In vitro growth inhibition of L5178Y-Parental murine leukemia cells2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID87507Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain KOS.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1205658Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake in presence of Na+ by liquid scintillation counting method2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.
AID1813511Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
AID43026Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Synthesis of 2'-deoxyuridine and 5-fluoro-2'-deoxyuridine derivatives and evaluation in antibody targeting studies.
AID1594184Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1292259Cytotoxicity against human MCF7cells after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID117346Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1292262Selectivity index, ratio of IC50 for HDF cells to IC50 for human HeLa cells2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID116953Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 100 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID589987Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID153603Evaluated for the antitumor activity in the P388 lymphocytic leukemia in female CDF1 mice injected intraperitoneally with 10 E-6 tumor cells dosed for 9 days at 20 mg/kg1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.
AID1675940AUC (0 to t) in NOD SCID nude mouse tumour xenografted with ZR-75-1 cells assessed as floxuridine; 5-fluoro-2-deoxyuridine AUC at 90 mg/kg, iv measured up to 24 hrs by HPLC-MS/MS analysis
AID124351Average weight change in treated P388 leukemia mice to that of control mice on administration of 200 mg/kg of compound in a q. d. 1-5 schedule1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1593892Cytotoxicity against human A549 cells at 1 uM treated 24 hrs post aerobic condition and measured after 72 hrs under aerobic condition by WST-8 assay relative to control2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
AID589768Antiviral activity against Reovirus 1 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID452067Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID451880Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675932Antitumour activity against human MIA-PaCa-2 cells xenografted in NOD SCID nude mouse assessed as tumour inhibition at 90 mg/kg, iv administered for 20 days measured every 2 day by caliper method relative to control
AID96473Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
AID124998Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID118985Median life span of the treated P388 leukemia mice to that of control mice after intraperitoneal administration of 50 mg/kg of compound in a q.d. 1-9 schedule; 10.5/10.91981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID452052Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1199985Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60 cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID133743The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID597792Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
AID1632123Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID451859Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1404378Antiparasitic activity against Cryptosporidium parvum SPL infected in human HCT8 cells incubated for 48 hrs by FITC/DAPI staining based fluorescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.
AID315587Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.
AID589872Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID118983Median life span of the treated P388 leukemia mice to that of control mice after intraperitoneal administration of 200 mg/kg of compound in a q.d. 1-5 schedule 12.0/11.91981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID372373Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID1135812Antimicrobial activity against Streptococcus faecium assessed as growth inhibition at 400 uM after 15 to 17 hrs by turbidity assay in presence of 4.53 nM folic acid1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID341995Antimicrobial activity against Escherichia coli ATCC 25922 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1205660Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake at 1000 uM in presence of Na+ by liquid scintillation counting method2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.
AID119492Number of deaths recorded in mice with P388 leukemia on days 1-5 after intraperitoneal administration of 600 mg/kg of compound in a q.d. 1-5 schedule; 0/61981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1135814Dissociation constant, pKa of the compound1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID451867Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID122434Life span ratio of P388 leukemia mice treated to that of control mice at dose 50 mg/kg, ip1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID221339Evaluation for antitumor activity against human lymphoblast Raji cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID589986Antiviral activity against Punta Toro virus infected in Vero cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID122621Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 67 mg/kg.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
AID1199991Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human SW707 cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID589877Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID128180Antitumor activity against transplanted tumor sarcoma 180 expressed as effective dose.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Studies on antitumor agents. 8. Antitumor activities of O-alkyl derivatives of 2'-deoxy-5-(trifluoromethyl)uridine and 2'-deoxy-5-fluorouridine.
AID101242The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -8)Mconc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID452050Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID119490Number of deaths recorded in mice with P388 leukemia on days 1-5 after intraperitoneal administration of 50 mg/kg of compound in a q.d. 1-9 schedule; 0/51981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Carbocyclic analogues of 5-fluorouracil nucleosides.
AID84062Antiviral activity against herpes simplex virus(1) strain 377.1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Carbocyclic analogues of 5-substituted uracil nucleosides: synthesis and antiviral activity.
AID1632125Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID220992Evaluation of antitumor activity against thymidine kinase deficient Raji cell line1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1632130Selectivity index, ratio of IC50 for HDF to IC50 for human MCF7 cells2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID1675903Toxicity in NOD SCID nude mouse xenografted with human MDA-MB-231 cells assessed as body weight at 90 mg/kg, iv for 20 days (Rvb = 30.1 +/- 4.1g)
AID1292266Selectivity index, ratio of IC50 for HDF cells to IC50 for human 143B cells2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID452060Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID452058Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID452065Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID99517Inhibitory concentration of compound was calculated on L5178Y cells by using clonal assay1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID130333The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 100 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1135805Antiviral activity against HSV1 CL101 infected in African green monkey Vero cells assessed as inhibition of plaque formation at 0.1 uM after 40 hrs relative to control1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1200006Antimicrobial activity against methicillin-resistant Staphylococcus aureus 572/12 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID452045Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID589980Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1293743Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HeLa cells2016European journal of medicinal chemistry, Jun-10, Volume: 115New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
AID156525Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [1,'2'-3H]dUrd1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and antiviral activity of 5-[(cyanomethylene)oxy]-2'-deoxyuridine.
AID231416Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 12.5 mg/kg, ip; 8/81980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2',5'-dideoxy- and 2',3',5'-trideoxynucleosides of 5-fluorouracil.
AID1292263Selectivity index, ratio of IC50 for HDF cells to IC50 for human KB cells2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID94497In vitro cell cytotoxicity was determined against KBALB-STK cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID452049Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID130343The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1131489Cytotoxicity against African green monkey Vero cells at 0.01 uM after 3 days by haemocytometry1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
A novel synthesis and biological activity of several 5-halo-5'-amino analogues of deoxyribopyrimidine nucleosides.
AID451874Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1200018Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 488/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID451854Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1675907Substrate activity at PEPT1 (unknown origin) expressed in MDCK cells assessed as inhibition of gly-sar uptake incubated for 10 mins by HPLC/MS/MS analysis
AID1304886Cmax in Sprague-Dawley rat plasma assessed as 5-FU formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID324742Ratio of Vmax to Km for Vaccinia virus WR thymidine kinase2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID1200015Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 468/11 after 18 hrs by two-fold serial microdilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID139288The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 67 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1304885Cmax in Sprague-Dawley rat plasma assessed as FDUR formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID139473The compound was tested for change in weight for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1675929Toxicity in NOD SCID nude mouse xenografted with human ZR-75-1 cells assessed as body weight at 90 mg/kg, iv for 20 days (Rvb = 29.2 +/- 2.5g)
AID452054Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1632128Selectivity index, ratio of IC50 for HDF to IC50 for human HeLa cells2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID130346The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 150 mg/kg1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
AID1135480Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID1304917AUC (infinity) in Sprague-Dawley rat liver assessed as FdUMP formation at 23.62 mg/kg administered through oral gavage measured up to 24 hrs by HPLC-MS/MS analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
AID301373Cytostatic activity against human CCRFCEM cells by MTT assay2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Cytostatic evaluations of nucleoside analogs related to unnatural base pairs for a genetic expansion system.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID589881Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.
AID1813513Cytotoxicity against human A549 cells after 24 hrs measured by MTT assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
AID452051Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
AID1199990Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LS180 cells2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis and biological activity of salinomycin conjugates with floxuridine.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,382)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901784 (52.75)18.7374
1990's697 (20.61)18.2507
2000's552 (16.32)29.6817
2010's287 (8.49)24.3611
2020's62 (1.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.13 (24.57)
Research Supply Index8.26 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index69.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials323 (9.08%)5.53%
Trials1 (1.79%)5.53%
Reviews208 (5.85%)6.00%
Reviews1 (1.79%)6.00%
Case Studies249 (7.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other2,776 (78.07%)84.16%
Other54 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (57)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients With Resected or Ablated Liver Metastases From Colorectal Cancer [NCT00268463]Phase 322 participants (Actual)Interventional2006-01-31Terminated(stopped due to The study was terminated due to low accrual.)
Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Contro [NCT02529774]Phase 2/Phase 3432 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Feasibility Pilot of Hepatic Arterial Infusion Chemotherapy in a Rural Catchment Area, Using the Codman Vascular Catheter With the Synchromed II Pump, for Patients With Unresectable Colorectal Cancer Liver Metastases or Unresectable Intrahepatic Cholangio [NCT04276090]21 participants (Actual)Interventional2020-05-01Terminated(stopped due to an alternate device became FDA approved)
Hepatic Artery Infusion Gemcitabine and Floxuridine in Patients With Nasopharyngeal Carcinoma Liver Metastases [NCT03876574]Phase 116 participants (Actual)Interventional2011-01-01Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer [NCT00059930]Phase 138 participants (Actual)Interventional2003-01-31Active, not recruiting
A Multi-center Randomized Controlled Trial: Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer [NCT02402972]Phase 3700 participants (Anticipated)Interventional2015-02-28Recruiting
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy [NCT00587067]Phase 234 participants (Actual)Interventional2003-06-30Completed
A Phase II Study of Induction Systemic mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone Given Concurrently With Systemic mFOLFIRI as a First-Line Therapy in Patients With Unresectable Liver-Dominant Intrahepatic Cholangio [NCT04251715]Phase 230 participants (Anticipated)Interventional2021-04-28Recruiting
A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases [NCT03856658]Phase 215 participants (Anticipated)Interventional2019-02-05Recruiting
A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer [NCT03069950]Phase 20 participants (Actual)Interventional2017-02-28Withdrawn(stopped due to Lack of accrual)
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver [NCT00019760]Phase 20 participants Interventional1999-04-30Completed
Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma [NCT05286814]Phase 248 participants (Anticipated)Interventional2022-10-24Recruiting
Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT00449163]Phase 225 participants (Actual)Interventional2006-03-01Terminated(stopped due to Study terminated by University of Miami Institutional Review Board)
Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma [NCT00002842]Phase 249 participants (Actual)Interventional1994-09-30Completed
A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial [NCT05863195]Phase 3408 participants (Anticipated)Interventional2023-12-19Not yet recruiting
A Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer. [NCT00695201]Phase 152 participants (Actual)Interventional2000-08-31Completed
A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma [NCT04891289]Phase 2164 participants (Anticipated)Interventional2021-05-07Recruiting
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma [NCT00296335]Phase 3855 participants (Actual)Interventional2002-02-28Completed
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver [NCT00001576]Phase 128 participants Interventional1997-07-31Completed
A Phase II Trial of Neoadjuvant Cisplatin-Fluorouracil-Docetaxel Chemotherapy, Surgery, and Intraperitoneal (IP) Floxuridine (FUdR) Plus Leucovorin in Patients With Locally Advanced Gastric Cancer [NCT00006038]Phase 20 participants Interventional2000-02-29Completed
A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma [NCT00448760]Phase 229 participants (Actual)Interventional2004-10-31Completed
Multicenter, Open-Label, Phase 2 Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Carcinoma [NCT00361842]Phase 265 participants (Actual)Interventional2006-07-31Completed
Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma [NCT01938729]Phase 18 participants (Actual)Interventional2013-09-05Completed
A Pilot Protocol Evaluating Safety of the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Advanced Colorectal Carcinoma or Cholangiocarcinoma [NCT04668976]Phase 2100 participants (Anticipated)Interventional2020-11-25Recruiting
A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) [NCT01862315]Phase 255 participants (Actual)Interventional2013-05-31Active, not recruiting
A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity [NCT00005860]Phase 10 participants Interventional2000-04-30Completed
Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and [NCT00858338]Phase 228 participants (Actual)Interventional2002-12-31Completed
A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis [NCT00408551]Phase 220 participants (Anticipated)Interventional2005-11-30Recruiting
Systemic Chemotherapy Plus HAI(FUDR)vs Systemic Chemotherapy Alone As Adjuvant Therapy in Patients With Resectable Colorectal Liver Metastasis [NCT03500874]Phase 3288 participants (Anticipated)Interventional2018-02-28Recruiting
Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases [NCT00522509]0 participants Observational1995-12-31Active, not recruiting
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes [NCT00492999]Phase 264 participants (Anticipated)Interventional2007-05-31Active, not recruiting
Phase II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-Fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma [NCT00183911]Phase 225 participants (Anticipated)Interventional2003-11-30Completed
A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065) [NCT00448682]Phase 225 participants (Actual)Interventional2005-06-30Terminated
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer [NCT00008294]Phase 10 participants Interventional2000-08-31Completed
A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver [NCT00020501]Phase 30 participants Interventional2001-03-31Completed
A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live [NCT00026234]Phase 275 participants (Actual)Interventional2002-02-28Completed
A Phase II Trial Of Toxicity Assessment In Two Cohorts Of Patients (Resection Alone Or Ablation With Or Without Resection Of Hepatic Metastases From Colorectal Cancer) Treated With Adjuvant Hepatic Arterial Infusion (HAI) FUDR Plus Systemic CPT-11 [NCT00063960]Phase 294 participants (Actual)Interventional2003-08-31Completed
A Randomized Phase-II Study of Patients With Locally Advanced Gastric of Gastro-Esophageal Adenocarcinoma Treated With Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine, Followed by Prolonged [NCT00848783]Phase 28 participants (Actual)Interventional2008-05-31Terminated(stopped due to Due to slow accrual)
A Pilot Protocol Evaluating Safety of Using the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Colorectal Carcinoma or Cholangiocarcinoma [NCT03693807]Phase 235 participants (Actual)Interventional2018-10-18Active, not recruiting
EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2 [NCT04898504]Phase 245 participants (Anticipated)Interventional2021-08-23Recruiting
Hepatic Arterial Infusion PUMP Chemotherapy Combined With systemIc chemoTherapy for Potentially Resectable Colorectal Liver Metastases: The PUMP-IT Study. [NCT04552093]Phase 2/Phase 331 participants (Anticipated)Interventional2020-09-09Recruiting
Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study [NCT01692704]Phase 1/Phase 212 participants (Actual)Interventional2012-04-30Completed
A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers [NCT01749397]Phase 129 participants (Actual)Interventional2012-12-07Completed
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients [NCT00001449]Phase 160 participants Interventional1995-09-30Completed
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER [NCT00002716]Phase 3135 participants (Actual)Interventional1996-01-31Completed
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma [NCT01525069]Phase 127 participants (Actual)Interventional2012-04-03Terminated(stopped due to Equipment that was used in the study was discontinued)
A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Primary Efficacy of LY01616 (Irinotecan Hydrochloride and Floxuridine Liposome Injection) in Patients With Advanced Solid Tumors [NCT05865925]Phase 1/Phase 278 participants (Anticipated)Interventional2021-04-22Enrolling by invitation
Phase II Study of Radiofrequency Ablation of Colorectal Cancer Liver Metastases Combined With Post-Ablation Hepatic Arterial Infusion of Floxuridine Alternating With 5-Fluorouracil [NCT00004142]Phase 240 participants (Actual)Interventional1998-08-05Completed
A PHASE II TRIAL OF NEOADJUVANT CISPLATIN-FLUOROURACIL CHEMOTHERAPY, SURGERY, AND INTRAPERITONEAL (IP) FLOXURIDINE (FUdR) PLUS LEUCOVORIN IN PATIENTS WITH GASTRIC CANCER [NCT00002783]Phase 250 participants (Anticipated)Interventional1996-05-31Completed
A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy [NCT00410956]Phase 255 participants (Anticipated)Interventional2007-05-31Active, not recruiting
Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies [NCT00005049]Phase 245 participants (Actual)Interventional1997-05-31Completed
A Phase I-II Study of Hepatic Arterial Therapy Via Pump (Protocol D97-063) With Floxuridine (FUDR) and Dexamethasone (DEX) in Combination With Intravenous Irinotecan as Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer [NCT00003753]Phase 20 participants Interventional1998-09-30Completed
FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM [NCT03678428]Phase 392 participants (Actual)Interventional2021-12-31Terminated(stopped due to Production halt of FUDR in China)
Systemic Chemotherapy With Irinotecan Plus Hepatic Arterial Infusion With Floxuridine and Oxaliplatin in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective Study [NCT03493061]Phase 260 participants (Actual)Interventional2018-02-01Completed
Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study [NCT02102789]Phase 3142 participants (Anticipated)Interventional2014-03-31Recruiting
A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy [NCT00004103]Phase 20 participants Interventional1998-07-31Completed
A Phase I/II Trial of Radioimmunotherapy (Y-90 cT84.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver [NCT00645710]Phase 1/Phase 216 participants (Actual)Interventional2005-02-11Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00002842 (1) [back to overview]2 Year Disease-free Survival .
NCT00296335 (3) [back to overview]Number of Patients With Adverse Events
NCT00296335 (3) [back to overview]Relapse-free Survival Rate
NCT00296335 (3) [back to overview]Overall Survival Rate
NCT00361842 (3) [back to overview]Progression-free Survival (PFS) Per RECIST Version 1.0
NCT00361842 (3) [back to overview]Duration of Response (DoR) Per RECIST Version 1.0
NCT00361842 (3) [back to overview]Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0
NCT00448760 (4) [back to overview]Pathologic Complete Response
NCT00448760 (4) [back to overview]Overall Survival
NCT00448760 (4) [back to overview]Median Progression-free Survival (PFS)
NCT00448760 (4) [back to overview]Clinical Response
NCT00449163 (4) [back to overview]Response Rate (Complete Response and Partial Response)
NCT00449163 (4) [back to overview]Median Progression-free Survival in Months
NCT00449163 (4) [back to overview]Overall Survival up to 2 Years
NCT00449163 (4) [back to overview]Rate of Toxicity in Study Participants
NCT00587067 (2) [back to overview]Median Survival
NCT00587067 (2) [back to overview]Number of Patients With Treatment Related Toxicity
NCT00645710 (4) [back to overview]Recommended Phase II Dose
NCT00645710 (4) [back to overview]Number of Participants With at Least One Dose Limiting Toxicity
NCT00645710 (4) [back to overview]Overall Survival
NCT00645710 (4) [back to overview]Progression-free Survival
NCT00848783 (1) [back to overview]Number of Patients With One-year Recurrence-free Survival
NCT04276090 (11) [back to overview]Percent of Patients Who Are Downstaged and Undergo Surgery
NCT04276090 (11) [back to overview]Percent of Patients That Require Secondary Intervention in Order to Obtain Primary Pump Function.
NCT04276090 (11) [back to overview]Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy
NCT04276090 (11) [back to overview]Number of Interventions (Phone Calls) to Assure Patients Attend Followup Appointments.
NCT04276090 (11) [back to overview]30-day Postoperative Serious Adverse Events Related to Pump Implantation
NCT04276090 (11) [back to overview]30-day Catheter Malfunction Due to Tubing Disconnect
NCT04276090 (11) [back to overview]Percent Pump Loss Due to Inability to Attend Scheduled Followup Appointments.
NCT04276090 (11) [back to overview]Percent of Screened Patients That Are Declined Due to High Risk of Failure as Determined by the Psychosocial Assessment Tool.
NCT04276090 (11) [back to overview]Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.
NCT04276090 (11) [back to overview]Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 3 Months.
NCT04276090 (11) [back to overview]30-day Catheter Malfunction Due to Inability to Access Pump

2 Year Disease-free Survival .

Estimated using the product-limit method of Kaplan and Meier. Disease free survival, defined as first documented evidence of treatment failure. Acceptable evidence includes: Anastomotic - positive cytology or biopsy; Abdominal, pelvic and retroperitoneal nodes - progressively enlarging node as evidenced by 2 CT scans separated by at least a 4 week interval, ureteral obstruction in the presence of a mass as documented on CT scan; Peritoneum - positive cytology or biopsy, progressively enlarged intraperitoneal solid mass as evidenced by 2 CT scans separated by at least 4 weeks; Ascites - positive cytology or biopsy; Liver - positive cytology or biopsy; Pelvic mass - positive cytology or biopsy, progressively enlarging intrapelvic solid mass as evidenced by 2 CT scans separated by at least 4 weeks; Abdominal wall - positive cytology or biopsy; Lung - positive cytology or biopsy or presence of multiple pulmonary nodules; Bone marrow - positive cytology, aspiration or biopsy. (NCT00002842)
Timeframe: 2 years after treatment

Interventionpercentage of participants (Number)
Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin9

[back to top]

Number of Patients With Adverse Events

Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years (NCT00296335)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
NeutropeniaAnemiaThrombocytopeniaFatigueDiarrheaNauseaVomiting
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati387413156391288371160
Mitomycin Plus Short-term Fluoropyrimidine262393101343219293104

[back to top]

Relapse-free Survival Rate

"Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.~Relapse was defined as any new tumor lesion." (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine67.0
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati64.9

[back to top]

Overall Survival Rate

Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery. (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine76.9
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati73.1

[back to top]

Progression-free Survival (PFS) Per RECIST Version 1.0

Progression-free survival (PFS) was defined as the time from the first dose to the documentation of progressive disease (PD), death, or lost to follow-up at last assessment visit. (NCT00361842)
Timeframe: Every 8 weeks

Interventionmonths (Mean)
Irinotecan - Naïve4.69
Irinotecan - Exposed3.48

[back to top]

Duration of Response (DoR) Per RECIST Version 1.0

The duration of overall response was measured from the time that measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of overall complete response was measured from the time measurement criteria were first met for complete response until the first date that recurrent disease was objectively documented. (NCT00361842)
Timeframe: Every 8 weeks

Interventionmonths (Median)
Irinotecan - NaïveNA

[back to top]

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0

Disease response was assessed using RECIST 1.0. Measurable disease and target lesions were determined prior to study entry. Changes in the largest diameter (unidimensional measurement) of the sum of the target tumor lesions were used in the RECIST criteria. Best response on study was classified as follows. Complete Response (CR), disappearance of all clinical and radiological evidence of tumor. Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of the longest diameters. Stable Disease (SD), steady state of disease. Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD. Progressive Disease (PD) at least a 20% increase in the sum of the longest diameters of measured lesions taking as references the smallest sum of longest diameters recorded since the treatment started. Appearance of new lesions also constituted progressive disease. (NCT00361842)
Timeframe: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

,
InterventionParticipants (Count of Participants)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
Irinotecan - Exposed001211
Irinotecan - Naïve02118

[back to top]

Pathologic Complete Response

No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy. (NCT00448760)
Timeframe: 8 - 16 weeks

Interventionpercentage of participants (Number)
Single Arm16.7

[back to top]

Overall Survival

(NCT00448760)
Timeframe: 24 months

Interventionmonths (Median)
Single Arm21.4

[back to top]

Median Progression-free Survival (PFS)

(NCT00448760)
Timeframe: 24 months

Interventionmonths (Median)
Single Arm13.6

[back to top]

Clinical Response

"Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:~Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.~Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions." (NCT00448760)
Timeframe: 8 - 16 weeks

Interventionpercentage of participants (Number)
Single Arm72.4

[back to top]

Response Rate (Complete Response and Partial Response)

Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0 (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab67

[back to top]

Median Progression-free Survival in Months

Median number of months subjects achieved progression-free survival (NCT00449163)
Timeframe: 2 years

Interventionmonths (Median)
Combination Chemotherapy and Bevacizumab13

[back to top]

Overall Survival up to 2 Years

Percentage of patients with overall survival times of up to 2 years (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab61

[back to top]

Rate of Toxicity in Study Participants

Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants. (NCT00449163)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Combination Chemotherapy and Bevacizumab50

[back to top]

Median Survival

Median Survival from Initiation of Hepatic Arterial Infusion (NCT00587067)
Timeframe: Up to 5 years

Interventionmonths (Median)
Floxuridine + Dexamethasone29.3

[back to top] [back to top] [back to top]

Number of Participants With at Least One Dose Limiting Toxicity

Dose Limiting Toxicity (DLT) defined as any treatment-related grade grade 3 nonhematologic toxicity not reversible to grade 2 or less within 24 hours, or any grade 4 toxicity.Up to three cycles of therapy were allowed with DLTs determined based on first cycle tolerance. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria version 2.0. (NCT00645710)
Timeframe: 4 weeks from start of treatment, up to 2 years.

Interventionparticipants with DLTs (Number)
Dose Level 1- FUdR 0.10 mg/kg/Day0
Dose Level 2 - FUdR 0.15 mg/kg/Day0
Dose Level 3 - FUdR 0.20 mg/kg/Day1

[back to top]

Overall Survival

Estimated using the product-limit method of Kaplan and Meier. Event defined as death due to any cause. (NCT00645710)
Timeframe: Up to 5 years

InterventionMonths (Median)
Dose Level 1- FUdR 0.10 mg/kg/Day23.2
Dose Level 2 - FUdR 0.15 mg/kg/Day73.2
Dose Level 3 - FUdR 0.20 mg/kg/Day41.2

[back to top]

Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression is defined as a 25% increase in the sum of products of measurable lesions over the smallest sum observed, or appearance of any lesions that had disappeared, or appearance of any new lesion/site. (NCT00645710)
Timeframe: Up to 5 years

InterventionMonths (Median)
Dose Level 1- FUdR 0.10 mg/kg/Day8.3
Dose Level 2 - FUdR 0.15 mg/kg/Day11.5
Dose Level 3 - FUdR 0.20 mg/kg/Day9.6

[back to top]

Number of Patients With One-year Recurrence-free Survival

This is defined as the patients who did not have recurrence of cancer at 1 year since the start of induction chemotherapy. (NCT00848783)
Timeframe: 1 year

Interventionparticipants (Number)
A-with IP Floxuridine3
B-Without IP Floxuridine2

[back to top]

Percent of Patients Who Are Downstaged and Undergo Surgery

The percent of patients who are downstaged and undergo surgery will be tabulated. (NCT04276090)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases7
Intrahepatic Cholangiocarcinoma0

[back to top]

Percent of Patients That Require Secondary Intervention in Order to Obtain Primary Pump Function.

Percentage of patients who need secondary intervention (IR embolization, revision of pump or tubing) to achieve primary pump function. (NCT04276090)
Timeframe: Approximately 4 weeks

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top]

Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy

The percent of patients who complete the 1st cycle of hepatic artery chemotherapy will be tabulated. This is a conglomerate safety endpoint which is a surrogate for any complication that prevents delivery of hepatic artery chemotherapy via the device combination. (NCT04276090)
Timeframe: approximately 4 weeks

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases16
Intrahepatic Cholangiocarcinoma4

[back to top]

Number of Interventions (Phone Calls) to Assure Patients Attend Followup Appointments.

The number of staff contacts (phone calls) to assure patients keep their followup visits will be tabulated. (NCT04276090)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top] [back to top]

30-day Catheter Malfunction Due to Tubing Disconnect

Quantify the percent of patients with inability to meet primary outcome due to catheter disconnects. (NCT04276090)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top]

Percent Pump Loss Due to Inability to Attend Scheduled Followup Appointments.

Percent of patients that experience pump loss/failure due to inability to attend scheduled followup appointments will be tabulated. (NCT04276090)
Timeframe: Approximately 6 months

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top]

Percent of Screened Patients That Are Declined Due to High Risk of Failure as Determined by the Psychosocial Assessment Tool.

Patients are screen using a psychosocial assessment tool for high risk of hepatic artery pump loss/failure, percent declined will be tabulated. (NCT04276090)
Timeframe: Immediate, determined at screening visit

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top]

Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.

The percentage of patients who remain on pump chemotherapy at 6months will be tabulated. (NCT04276090)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases13
Intrahepatic Cholangiocarcinoma3

[back to top]

Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 3 Months.

The percentage of patients who remain on pump chemotherapy at 3 months will be tabulated. (NCT04276090)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases14
Intrahepatic Cholangiocarcinoma4

[back to top]

30-day Catheter Malfunction Due to Inability to Access Pump

Quantify the percent of patients with inability to meet primary outcome due to inability to access pump. (NCT04276090)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Colorectal Liver Metastases0
Intrahepatic Cholangiocarcinoma0

[back to top]